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ABSTRACT 
 
Diffuse Optical Imaging for Monitoring Peripheral Arterial Disease Revascularizations 
 
Jennifer W. Hoi 
 
Peripheral arterial disease (PAD) affects approximately 200 million individuals worldwide. It is 
characterized by a reduction in blood flow to the lower extremities due to atherosclerosis. This 
can result in leg pain, tissue loss, and ultimately amputation. Revascularization procedures aim to 
restore blood flow, but up to 50% of patients require another intervention within a year. 
Revascularization monitoring and early detection of failure are crucial in preventing limb loss 
and adverse cardiovascular events. However, current evaluation methods do not directly measure 
perfusion and are limited in a significant segment of PAD patients, such as those with diabetes 
and renal insufficiency. Diffuse optical imaging (DOI) techniques are promising tools to 
overcome these limitations. Employing near-infrared light, they are non-invasive, non-ionizing, 
contrast-free, and cost-effective methods that are sensitive to hemodynamic parameters such as 
changes in oxy-, deoxy-, and total hemoglobin concentration, making DOI ideal for 
revascularization monitoring. 
In this dissertation, I investigate and develop DOI systems for the purpose of monitoring 
lower extremity revascularization procedures in PAD patients. We utilize a contact-based diffuse 
optical spectroscopy (DOS) system to monitor localized foot perfusion in an ongoing clinical 
study of 100 patients undergoing lower extremity angiography. I demonstrate the utility of DOS 
measurements to provide valuable insights into revascularization related hemodynamic 
remodeling and to predict revascularization success. Furthermore, I also develop a clinic friendly 
contact-free diffuse optical tomography (DOT) system that is better-suited for PAD patients with 
ulcers. I show that this system can provide spatial maps of perfusion within the foot. 
Collectively, this work establishes diffuse optical imaging as a valuable imaging modality for the 
evaluation of lower extremity perfusion.  
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1.1 Overall Goals and Outline 
The overall goal of this dissertation is to develop and investigate diffuse optical imaging (DOI) 
techniques for monitoring revascularization procedures in patients with peripheral arterial 
disease (PAD). Accurate monitoring of perfusion after revascularization has the potential to 
improve patient outcomes by informing clinicians early on which patients may benefit from 
additional therapy. DOI techniques such as diffuse optical spectroscopy (DOS) and tomography 
(DOT) are well-suited for repeated perfusion measurements in PAD patients since these 
techniques are sensitive to functional changes in the tissue without the use of ionizing radiation 
or exogenous contrast agents. To investigate and develop DOI techniques for revascularization 
monitoring, I pursue the following specific aims: 
 
Specific Aim 1: To investigate the utility of diffuse optical spectroscopy (DOS) in post-
revascularization monitoring of PAD patients in a clinical pilot study.  
Rationale: Up to 50% of PAD patients undergoing revascularization need another intervention 
within 12 months. A method of monitoring the blood perfusion post-intervention may be useful 
in early detection of whether the intervention was successful.   
Approach: 100 PAD patients undergoing peripheral angiography are imaged using a DOS system 
in a longitudinal study. The patients are imaged before and after the procedure. Patients receiving 
revascularization will be imaged with DOS at post-operative follow-up visits over the course of a 





Impact: This study will reveal the utility of DOS perfusion measurements in monitoring 
revascularization and provide critical information for future studies. 
 
Specific Aim 2: To design and implement a multi-view contact-free diffuse optical 
tomography (DOT) imaging system for assessing perfusion in the lower extremities. 
Rationale: DOS depends heavily on the location of the measurement probe and fiber-based DOT 
systems are not ideal in the clinical setting due to open wounds and cumbersome fiber 
placement.  
Approach: A wide-field camera sensor and ray transfer function are utilized to develop a DOT 
system that employs both reflection and transmission light detection with a fiber-free interface.  
Impact: This is the first clinically oriented DOT system that simultaneously collects multiple 
views with a fiber-free patient interface for easy setup. 
 
Specific Aim 3: To characterize and validate the DOT system in phantoms and healthy feet. 
Rationale: The capability of the DOT system to accurately reconstruct hemoglobin-dependent 
parameters in the foot and spatially and temporally resolve the locations of those areas is 
important in the evaluation of PAD. Additionally, the system must be able to provide consistent 
measurements over time in order to monitor the response to surgical intervention.  
Approach: The ability of the system from Specific Aim 2 to reconstruct the spatial-temporal 
distribution of hemoglobin-dependent parameters is characterized and validated using numeric 
simulations, tissue mimicking phantoms, and healthy feet.  
Impact: This demonstration of the system’s ability to collect and accurately reconstruct regions 






The pursuit of these aims introduces valuable information and technology for the application of 
DOI to improving patient care in the diagnosis and management of PAD. The following sections 
in this chapter provide a background on PAD and DOI techniques. Chapter 2 describes the 
methods and results related to the study associated with Specific Aim 1. In Chapter 3, the design 
and implementation of the novel contact-free DOT system developed for Specific Aim 2 is 
described. The characterization and validation of the DOT system is detailed in Chapter 4. 
Finally, in Chapter 5, a summary and future outlook of this work is presented. 
 
1.2 Peripheral Arterial Disease (PAD) 
1.2.1 Etiology and Symptoms 
Peripheral arterial disease (PAD) affects approximately 8 to 12 million individuals in the United 
States and over 200 million worldwide [1, 2]. It is a systemic disease characterized by the 
narrowing of arteries that supply the lower extremities with blood.  This stenosis is primarily 
caused by atherosclerosis, or the accumulation of plaque between the intimal and medial layers 
of the arterial vessels. Atherosclerotic plaque is composed of fatty substances, cholesterol, 
calcium, fibrin, and cell waste products. The narrowed arteries results in compromised blood 
flow to the legs and feet [3].  
 Patients are often asymptomatic, but ischemic symptoms can result when there is an 
imbalance between the compromised supply of blood and the metabolic demand for blood. 
Arterial insufficiency leads to tissue hypoxia and can cause intermittent claudication (IC), or 





location and severity of the arterial stenosis, the collateral circulation, and the activity level of 
the patient. The disease follows anatomic patterns and stenosis is usually well localized in the 
proximal or middle segments of the lower extremity arterial network. However, patients with 
diabetes mellitus (DM) or end-stage renal disease (ESRD) generally have more distal stenoses 
(e.g. in the tibial vessels and foot). In general, the leg pain location is associated with the stenosis 
site. The severity of pain can range from mild discomfort to debilitating and lifestyle-limiting 
pain. IC is often quantified by the walking distance before the onset of pain, which gradually 
decreases as the disease progresses [4]. In the most severe form of PAD, pain can be present 
even at rest. 
 Furthermore, chronic arterial insufficiency can lead to critical limb ischemia (CLI), 
which is defined as rest pain (typically localized at the distal forefoot and toes), ulcers, and 
gangrene [5]. Patients with CLI have an elevated risk of limb loss with a 25% amputation rate [6, 
7]. There are multiple factors contributing to the threat of limb loss, including under-perfusion, 
the extent and severity of wounds, and the presence and severity of infection. Ischemic foot 
ulcers can become infected, which may lead to osteomyelitis and gangrene, and amputation is 
often necessary to prevent sepsis. Lack of perfusion to the wound contributes to delayed wound 
healing and increased amputation risk [8]. Over 80% of diabetes-related amputations are 
preceded by non-healing foot ulcers [9]. Additionally, patients that fail to heal their wounds 
suffer high mortality rates. Thus, revascularization is necessary to prevent limb loss and prolong 
survival [2]. Without revascularization, 34% of CLI patients will have undergone a major 
amputation and 20% will have died [10]. CLI is associated with multilevel disease, or any 
combination of iliac, femoral or tibial vessel stenosis. Figure 1-1 shows the levels of the arterial 







Figure 1-1: Graphic depicting the general lower extremity arterial vascular tree 
 
However, most patients with PAD are unaware of their disease. Fewer than 50% of individuals 
with PAD and approximately 30% of their physicians are aware that PAD is present [11]. There 
are up to three times as many asymptomatic patients as symptomatic patients [12].  It is 
estimated that of PAD patients ≥50 years old, 20-50% are asymptomatic, 40-50% exhibit 
atypical leg pain, 10-35% exhibit IC, and 1-2% have CLI [6, 13]. 10-20% of patients with IC 
have worsening symptoms [6, 14-16]. The risk for progressing to CLI is 4-times higher in 
patients with diabetes, 3-times higher in patients who smoke, and 2-times higher in patients with 
hypercholesterolemia [17, 18]. 
 The risk factors associated with the development of PAD include old age, smoking, 
hypertension (HTN), hyperlipidemia (HLD), and diabetes [19, 20]. The PAD population with 
Common Femoral Artery (CFA)
Superficial Femoral Artery (SFA)
Tibioperoneal Trunk (TPT)
Popliteal Artery (POPA)
Deep Femoral Artery (DFA)
Anterior Tibial Artery (ATA)







comorbid diabetes and chronic kidney disease is especially important since limb loss and 
survival is significantly worse for them [21-23]. In diabetic patients, peripheral neuropathy and 
increased susceptibility to infection contribute to the 5- to 10-times higher amputation rate [21]. 
Currently, 85% of lower extremity amputations occur within diabetic patients and results in over 
71,000 amputations annually.  
In addition, PAD patients are at high risk for coronary heart disease, heart attacks, and 
stroke [2]. Approximately 15-30% of symptomatic PAD patients die within 5 years, mainly due 
to stroke and myocardial infarction [3, 6, 14, 15], with 45,000 dying of PAD-related causes per 
year in the US [24]. Thus, timely diagnosis, successful treatment, and frequent monitoring of 
PAD are crucial in preventing future cardiovascular events [25].  
 Patients with PAD can manage the disease with lifestyle modifications, risk factor 
treatments, and medical management. Continued smoking is a major factor in PAD progression 
and smoking cessation is recommended for all PAD patients. Management also includes 
antiplatelet therapy, lipid-lowering therapy, exercise therapy, and control of blood sugar, blood 
pressure, and weight. These treatments aim to relieve symptoms and lower the risk of future 
cardiovascular events such as myocardial infarction and stroke. Antithrombotic (antiplatelet) 
therapies with aspirin or clopidogrel and lipid-lowering therapies with statins can significantly 
reduce the risk for future adverse events [12, 26-29]. Successful medical management can also 
reduce non-calcified atherosclerosis. However, patients may need a revascularization procedure 
to restore blood flow if symptoms persist. The management of PAD is responsible significant 
health care resource utilization with over 2,750,000 office visits per year and 275,000 hospital 





1.2.2 Current Methods to Evaluate PAD 
Multiple vascular testing methods are used to assess the presence and severity of PAD, in 
addition to a physical examination of the peripheral skin, pulses, and neurologic status.  
1.2.2.1 Ankle Brachial Index (ABI) 
The ankle-brachial index (ABI) is the first-line diagnostic test for PAD. It is a ratio of the 
resting systolic blood pressure at the ankle to the systolic blood pressure at the arm.  The systolic 
blood pressure of the dorsalis pedis (DP) and the posterior tibial (PT) arteries are measured using 
a pressure cuff around the ankle and continuous-wave Doppler, as depicted in Figure 1-2(a). The 
systolic brachial artery pressures of both arms are also measured similarly using pressure cuffs 
around the upper arm. The pressure index for each ankle artery (ABI-DP and ABI-PT) is 
calculated by dividing the systolic ankle pressures by the higher of the two systolic brachial 
artery pressures. Traditionally, the higher of the pressure indexes is used to represent the overall 
ABI, but the lower of the two pressure indexes is generally used to identify at-risk patients 
(Figure 1-2(b)). 
An ABI between 0.9 and 1.3 is considered normal, but an ABI of <0.9 is indicative of 
PAD. The ABI can reflect the severity of the disease. For example, most patients with IC have an 
ABI between 0.5 and 0.8 and patients with CLI generally have an ABI less than 0.5. ABI 
changes >0.15 over time are considered significant and suggests disease progression. Larger ABI 









Figure 1-2: (a) Graphic depicting systolic ankle pressure measurement and  
(b) ABI calculation scheme (adapted from [31]) 
 
While the ABI measure has been generally accepted, concerns have been raised regarding its 
validity [32-34]. In CLI patients undergoing revascularization, almost 25% had a normal ABI 
and less than 17% had severe ABI [34]. Patients with diabetes or chronic kidney disease often 
have medial wall calcification and hardened arteries. When arteries are hardened, the systolic 
blood pressure measurement using pressure cuffs reflects the stiffness of the wall rather than the 
blood flow and pressure within the artery. This results in ABI measurements that are falsely 
elevated according to the degree of hardening. For completely incompressible arteries, the ABI is 
>1.3. False-negative ABI measurements can occur in a third of limbs in diabetic patients [2]. 
Thus, the utility of ABI is limited in the diabetic and chronic renal insufficiency populations. 
There are large implications for the use of ABI as a screening and evaluation tool, given that the 






to 40% of the PAD population [35]. Furthermore, ABI measures can be misleading because it 
provides assessment at the level of the ankle, but most tissue loss is distal to the ankle.  
1.2.2.2 Segmental Pressures 
The location and extent of PAD can be determined by measuring segmental pressures. Similar to 
ABI measurements, systolic blood pressures are measured at the pedal arteries with the pressure 
cuff placed at successive levels of the extremity (i.e. high thigh, low thigh, calf, and ankle). This 
allows for the localization of the disease to various segments of the limb by calculating of the 
pressure index at each level of the extremity. As with ABI measurements, segmental pressure 
measurements may be artificially elevated in hardened arteries limiting its ability to localize 
stenoses. Furthermore, pressure indices may be normal even in the presence of lesions if the 
collateral vasculature is well-developed around the lesions. 
 
Figure 1-3: (a) Graphic of pressure cuff placement for segmental pressures and PVR and  








1.2.2.3 Pulse Volume Recordings (PVR) 
Pulse volume recordings (PVR) attempt to localize a stenosis or occlusion. PVR can be 
measured in conjunction with segmental pressures using the same pressure cuffs along the limb 
Figure 1-3(a). In PVR measurements, these pressure cuffs are inflated sequentially to 65mmHg. 
Volume changes in the limb segment beneath the pressure cuff are reflected in changes in the 
pressure within the cuff itself. The pressure changes within the cuff are measured by a pressure 
transducer to provide a PVR waveforms. Examples of PVR waveforms are shown in Figure 
1-3(b). The shape of the trace reflects the presence and severity of arterial lesions. A normal 
PVR waveform is characterized by a rapid systolic upstroke with a sharp peak followed by a 
down stroke with a prominent dichrotic notch. Mild to moderately abnormal waveforms are 
characterized by the loss of the dichrotic notch and a slower down stroke. In severely abnormal 
waveforms, the amplitude is significantly attenuated, but the absolute amplitude of the waveform 
is not used to interpret the waveforms since it is influenced by cardiac output and vasomotor tone.  
PVR can be useful in detecting disease in calcified arteries which falsely elevate pressure 
measurements.  
1.2.2.4 Arterial Duplex Ultrasound (DUS) 
Duplex ultrasound (DUS) of the arteries is usually used as secondary method to confirm initial 
diagnostic findings, to assess potential revascularization by localizing arterial stenosis, and to 
evaluate previous revascularizations in post-intervention surveillance protocols [36]. DUS can 







Figure 1-4: Classification of Doppler waveforms that indicate the degree of stenosis 
(adapted from [37]) 
 
DUS combines B-mode imaging to produce an image of vascular structures and Doppler mode to 
assess the blood flow velocity. The technician looks for lesions along the arterial vasculature 
(from the common fermoral artery to the tibial vessels) by moving the Doppler probe along the 
leg and listening for bruits and pitch changes resulting from blood flow through narrowed 
arteries. Measurements of blood flow velocity using the Doppler shift require the proper 
positioning of the ultrasound probe relative to the direction of flow. The Doppler velocity 
waveforms can also be categorized as triphasic (normal), biphasic, and monophasic. These are 
shown in Figure 1-4. Since the velocity waveform is dependent on whether the probe is proximal 
or distal to a stenosis, the severity of a stenosis is best assessed by positioning the Doppler probe 
directly over the lesion. 
The ratio of the peak systolic velocity (PSV) within an area of stenosis is compared with 
the PSV in the vessel just proximal to it to estimate the degree of stenosis. For the lower 
extremity, the percent stenosis can be estimated. A PSV ratio that is 1.5 - 2.0 indicate a 30-49% 
stenosis, 2.0 – 4.0 indicate a 50-75% stenosis, and >4.0 indicate a >75% stenosis in the 
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peripheral arteries. This technique works well in measuring flow in large vessels, but becomes 
difficult in the small vessels below the knee. As the arteries decrease in size, the results are 
increasingly user-dependent and fails to visualize up to 15% of arterial segments in the calf [38]. 
1.2.2.5 Angiography 
Angiographic methods are usually reserved for patients with inconclusive non-invasive vascular 
testing, or for patients where intervention is anticipated. Contrast angiography is used to define 
the arterial anatomy prior to intervention and involves the intravascular injection of a contrast 
agent during imaging. These methods have better spatial resolution then duplex ultrasound and 
include computed tomography angiography (CTA), digital subtraction angiography (DSA) [39], 
and magnetic resonance angiography (MRA). In DSA, the base CTA images are enhanced by 
digital background subtraction of a pre-contrast frame allowing only the contrast agent in the 
arterial system to be seen on the image. DSA provides superior contrast resolution with lower 
doses of intravenous contrast compared with non-digital techniques. CTA and DSA also allows 
for simultaneous intervention, termed an interventional angiogram. CTA or DSA without 
intervention is referred to as a diagnostic angiogram. 
However, CTA and DSA require the use nephrotoxic contrast agents [40, 41]. This limits 
their use in patients with reduced renal function, a common occurrence in PAD patients with 
diabetes.  In addition, DSA and CTA use ionizing radiation and are not suitable for routine 
monitoring of PAD progression or response to therapy [42]. MRA does not use ionizing 
radiation, but still requires the administration of nephrotoxic contrast and MRA of small vessels 
is not sufficient for diagnosis or treatment planning. Furthermore, the high costs and sensitivity 





1.2.3 Revascularization in PAD Patients 
1.2.3.1 Revascularization Procedures 
PAD patients, especially those with CLI, will often require revascularization to restore adequate 
blood perfusion, limit tissue loss, and mitigate cardiovascular events. Over 100,000 PAD related 
surgeries are performed in the United States annually, including percutaneous interventional 
procedures and surgical bypass. Both revascularization techniques aim to increase the blood 
perfusion in the lower extremity.  
Percutaneous, or endovascular, interventions are a less invasive alternative to surgical 
revascularization in patients with CLI and attempt to open a stenosis in the artery. Endovascular 
procedures involve accessing the femoral artery with an arterial sheath and passing various wires 
and catheters to guide the placement of an expandable balloon, stent, or atherectomy device. In 
balloon angioplasty, a collapsed balloon is inflated to a fixed size using water pressure. The 
balloon crushes the plaque, dissecting the arterial media, and widening the lumen of the stenosed 
vessel. A stent can also be placed at the same location if the vessel does not remain patent or the 
dissection progresses [43]. Drug coated balloons (DCB) and drug-eluting stents (DES) are coated 
with drugs to decrease restenosis due to fibrointimal hyperplasia [44]. Unlike angioplasty and 
stenting, which crack atherosclerotic plaque and push it out of the way, atherectomy involves the 
removal of plaque using physical (e.g. cut) or ablative (e.g. laser) means. These methods can be 
used primarily or in combination with each other to treat each arterial stenosis.    
Surgical revascularization, namely vascular bypass, is more invasive than endovascular 
procedures. Vascular bypass involves identifying an appropriate vessel above and below the 





autogenous vein or prosthetic material, though most surgeons avoid prosthetic material if 
possible. Cumulative patency rates are higher for femoropoliteal reversed saphenous vein grafts 
compared with PTFE (85 versus 68 percent at one year)[45] and the primary patency of 
infrapopliteal PTFE grafts is 12 to 41% at 3-5 years [46-48].  
The decision between endovascular or surgical intervention, or a combination of these, 
depends upon the level of obstruction (e.g. aortoiliac, femoropopliteal), severity of disease, 
anatomic pattern of arterial disease, distal vessel runoff relative to regional tissue ischemia, 
variation in arterial anatomy (e.g. collateralization), the patient’s comorbidities, the patient's risk 
for the intervention, the patient’s prior arterial interventions, the patient’s preference, and the 
goals for care.  
TASC-II describes atherosclerotic patterns of disease in the proximal limb according to 
their anatomic distribution, multiplicity of lesions, and the nature of the lesion (stenosis or 
occlusion) and groups them based upon overall success rates using endovascular or surgical 
means. In general, atherosclerotic patterns that favor endovascular therapy (Type A, Type B) are 
simpler short segments of disease versus complex long segments which favor surgery (Type D, 
Type C). Lesions that display unfavorable anatomy for a percutaneous approach reflect more 
extensive disease and are typically associated with more severe morphologies (long-segment 
stenosis, multifocal stenosis, eccentric and calcified stenosis, and long segment occlusions). 
However, the TASC-II classification does not provide guidance for the treatment of tibial vessel 
disease and does not address the multilevel disease typical for CLI patients [2]. The success of 
endovascular procedures is directly related to the tibial runoff [49, 50] and distal-level PAD is 





With the widespread availability and advancements of percutaneous procedures, major 
cardiovascular society guidelines recommend initial endovascular revascularization, reserving 
bypass for those with arterial anatomy for which an endovascular approach is not likely to 
provide a durable clinical success [52-55]. Outcomes for CLI patients have improved over time 
possibly due to the more liberal use of endovascular intervention [56]. 
 
1.2.3.2 Revascularization Surveillance 
Follow-up of revascularization procedures consists of periodic clinical evaluations that should 
note any return or progression of symptoms, wound healing progression, the presence of pulses, 
ABI measurement, and DUS imaging of the entire length of the graft to evaluate graft stenosis 
[6].  
Bypass graft patients are monitored for life for graft stenosis. Vein graft stenosis develops 
in 20 to 30 percent of infrainguinal vein bypasses during the first year and can lead to graft 
failure. Grafts that are carefully monitored following grafting and in which a detected stenosis is 
addressed (eg, balloon angioplasty or bypass of the stenotic segment) do far better in the long 
term than grafts that are revised only following complete thrombosis. Untreated, high-grade 
intrinsic graft stenosis almost universally result in graft occlusion. DUS is considered the best 
method for detecting graft stenosis [57-61]. Similarly, early and ongoing surveillance of 
following infrainguinal percutaneous intervention may identify impending failures, but the use of 





1.2.3.3 Revascularization Outcome Measures 
Success after intervention for claudication may be measured anatomically, hemodynamically, 
and functionally. While anatomic patency and hemodynamic success are important, the primary 
reason to perform an intervention is to provide effective reperfusion for symptom relief and long-
term clinical success. Following intervention, clinical success is often higher than anatomic 
success. Clinical failures are only partially related to anatomic patency of the treated area, and 
other factors, such as progression of disease in the inflow vessels, in the treated vessel, and in the 
outflow tract, are also implicated. The overall prognosis of the patient with PAD depends on the 
specific vascular beds that are more predominantly affected and the presence of risk factors and 
comorbidities for PAD [64, 65].  
 The Society of Vascular Surgery (SVS) has adopted objective performance goals to 
assess cross-platform interventions in a patient-centric manner, including major adverse 
cardiovascular events (MACE), 30-day major adverse limb events (MALE) and 30-day 
amputation rate, amputation-free survival (AFS), and freedom from MALE [66]. Symptom relief 
measures include claudication distances, ulcer healing rates, healing rates.  
 ABI is considered a measure of hemodynamic success and is defined as an increase of 
0.15. Most studies have shown an appropriate increase in ABI after intervention. However, the 
magnitude of change may or may not correlate with symptomatic improvement. 
 Anatomic patency after perioperative technical success of a revascularization is generally 
obstructed by graft or stent thrombosis, vein graft stenosis, in-stent stenosis, and new native 
vessel stenotic lesions. The SVS defines the anatomically patency of the intervention as:  
• Primary patency – patency that is obtained without the need for an additional or 





• Assisted primary patency  patency achieved with the use of an additional or secondary 
endovascular procedure as long as occlusion of the primary treated site has not occurred. 
• Secondary patency - patency obtained with the use of an additional or secondary surgical 
procedure once occlusion occurs. 
This enables evaluation of time to primary failure (e.g. occlusion or need for intervention) and 
the time to final failure after multiple interventions and revisions. The assisted patency rates for 
vein bypass ranges from 65-90% at five years [6]. It is estimated that vein graft stenosis develops 
in 20-30% of infrainguinal vein bypasses during the first year, which can often lead to graft 
thrombosis and failure. Intervention based upon a DUS surveillance protocol has resulted in five-
year assisted patency rates of 82-93%, significantly higher than the 30-50% secondary patency 
rates of thrombosed vein grafts [67]. 
Compared with bypass, endovascular interventions are associated with higher rates of 
restenosis, which can usually be managed with repeat intervention [68]. Patency rates vary 
greatly depending on the anatomic pattern and severity of the lesions. Primary patency tends to 
decrease the more distal the disease and intervention. Smaller vessel diameter is one possible 
reason for the higher rate of restenosis at this site. Other anatomic factors that adversely affect 
long-term patency following angioplasty of the femoropopliteal segment include long or 
eccentric calcified lesions, arterial occlusion, and poor distal runoff [69, 70]. 
Angioplasty of uncomplicated iliac lesions have assisted primary and secondary patency 
rates are >95% [71, 72]. Femoropopliteal lesions can be challenging to treat using an 
endovascular approach because of the mobility of this segment with extremity movement [73-
75]. Angioplasty in the femoropopliteal segment is associated with high rates of restenosis. In IC 





often due to restenosis, which usually occurs in the first six months, or due to progressive 
atherosclerosis at the lesion site or elsewhere in the same vessel [69]. Interestingly, repeat 
angioplasty has equivalent patency rates to initial angioplasty [76]. Primary stenting (self-
expanding or balloon expandable) may be advantageous when managing calcific or long segment 
lesions [77]. Endovascular treatment of infrapopliteal lesions is much lower than more proximal 
counterparts. In one study, only 42% of the treated lesions were patent at two years [78].  
In recent years, advances in endovascular interventions such as DCB and DES aim to 
improved patency at all levels of intervention. For example, the ZILVER PTX trial compared 
primary placement of DES to angioplasty in SFA lesions. Significantly improved primary 
patency was seen in the DES group compared with angioplasty at two years (75% versus 27%) 
[79-83]. Overall, primary patency, freedom from target lesion revascularization, and clinical 
improvement at one year are significantly higher in with DES compared to bare metal stents [84-
86]. 
Despite technical success and patency, some patients still have non-healing ulcers, 
experience amputation, or require further intervention. Patency alone does not determine/predict 
limb salvage. 10% of patients with a patent bypass graft required major amputation or had 
ongoing ischemia 1 year post-revascularization. In a meta-analysis of lower extremity 
angioplasty vs pop-distal bypass, 3 yr arterial patency rates were lower for angioplasty (49%) 
than bypass (72%), although limb salvage rates were equivalent at 82%. Despite technically 
successful revascularizations, restoring pedal pulses, and achieving vessel patency, up to 15% of 
CLI revascularization procedures performed still result in with ulcer healing failure and limb loss 





vessel and the site of ulceration might be part of the reason why ischemic ulcerations persist and 
or deteriorate despite technically successful revascularizations.  
The underlying pathology behind critical limb ischemia and the significant rate of 
unhealed wounds and secondary amputations despite apparently successful revascularization 
needs to be addressed. In seeking to improve outcomes, it may be beneficial to examine our 
approach to vascular disease at the fundamental level of anatomy, the angiosome, to better 
dictate reperfusion strategies beyond a simple determination of open vs endovascular procedure. 
A clear need to understand these physiological processes further and for methods to measure the 
distal perfusion in the foot to obtain better outcomes.  
1.2.4 Angiosome-directed Revascularization 
Traditionally, revascularization planning has been based on the ‘best vessel’ approach where the 
least diseased artery that supplied the best runoff to the foot was revascularized or used as the 
outflow artery for a distal bypass. Restoring in-line flow to the foot via any tibioperoneal artery 
was thought to be sufficient for wound healing. Higher incidences of amputation despite 
technically successful revascularizations have been reported in diabetic patients, for which a 
failure to reperfuse the site of tissue loss is identified as a leading factor [92]. 
To address this discrepancy, the angiosome concept has found increasing attention in the 
vascular surgery community over the last decade [93-112]. First described in 1987, the 
angiosome concept delineates that a 3D volume of tissue has its blood supplied by a specific 
source artery [101]. This concept was applied to the management of PAD in 2006 [107]. There 






Figure 1-5: Six angiosomes of the lower extremity (adapted from [113]) 
 
A network of collateral arteries provides anatomic connections between angiosomes. These 
collaterals provide indirect flow from a well-perfused angiosome to a neighboring angiosome if 
its source artery is occluded. Medium-sized collaterals (arterial-arterial connections, >0.5mm), 
including the plantar arch and the distal peroneal branches, arise from distal tibial vessels and its 
branches to allow the development of alternative routes of blood if the direct route is 
compromised [102, 107]. Small-sized collaterals (choke vessels, <0.5mm) also interconnect the 
vascular territories. Choke vessels are small blood vessels that exist between angiosomes and are 
collapsed in a low flow state. When an adjacent angiosome become ischemic, a pressure gradient 
develops and flow is diverted via choke vessels into the ischemic territory. Over time, these 
vessels dilate and are termed “collaterals”. It is critical to note that choke vessels take time (days 
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vessel occlusion. Factors that affect the ability of choke vessels to become more or less able to 
dilate to support an adjacent vascular territory include age and smoking.  
According to this concept, a direct in-line of blood flow can be specifically restored to an 
ischemic angiosome in direct revascularization (DR) as opposed to restoring blood flow to the 
underperfused angiosome indirectly via collaterals in indirect revascularization (IR). Angiosome-
directed revascularization maximizes the blood flow to an affected region rather than simply 
improving global undirected flow to the foot.   
Clinical evidence continues to mount for the efficacy of angiosome-directed 
revascularization, particularly for infrapopliteal endovascular revascularizations to treat pedal 
ulcers in CLI patients and mitigate limb loss [77, 100, 103, 104, 106, 107, 114-125]. Patients that 
fail to heal their wounds suffer high mortality rates. Wound healing in critical limb ischemia 
often requires improving blood flow to the wound. Treatment based on the angiosome concept 
can help wounds to heal and may preserve limbs. While DR has not seen significant 
improvement for infrapopliteal bypass procedures compared to IR [106, 110], DR does seem to 
produce better outcomes for infrapopliteal endovascular procedures. Higher rates of healing and 
limb salvage are associated with DR versus IR [114-116]. However, the results for the benefits 
of DR for the rate of limb salvage (AFS and MALE) with DR are mixed [123]. This discrepancy 
could be because infected wounds are associated with higher amputation rates despite successful 
reperfusion of the wound bed.  
Although there are important limitations in these angiosome-guided revascularization 
studies, the 2016 AHA/ACC update on the guideline on the management of patients with lower 
extremity PAD suggests the use of angiosome-directed endovascular revascularization for CLI 





1.3 Diffuse Optical Imaging of PAD 
1.3.1 Diffuse Optical Imaging Background 
Optical imaging methods are sensitive to functional parameters such as blood volume and have 
tremendous potential to directly address this clinical need.  
Optical measurement techniques can non-invasively measure blood in tissue without the 
need for contrast agents or ionizing radiation. In functional optical imaging, non-ionizing red and 
near-infrared (NIR) light (650nm < λ < 900nm) is used to probe biological tissues. This 
wavelength range is unique because light absorption is relatively low enabling deep penetration 
in tissue. Additionally, light is mostly absorbed by the blood constituents deoxyhemoglobin (Hb) 
and oxyhemoglobin (HbO2). These chromophores have characteristic absorption spectra 
allowing for the calculation of their concentrations when multiple wavelengths are used. By 
illuminating the tissue from multiple positions and detecting the re-emitted light from multiple 
positions, the intrinsic optical properties of the tissue are reconstructed and the Hb and HbO2 
concentrations are derived by modeling the light propagation through the tissue being probed 
given the geometry of the light source and detection.  
1.3.1.1 Light-tissue interactions 
Light is absorbed and scattered as it propagates through tissue. The amount of absorption and 
scattering is dependent on the wavelength of light and the optical properties of the tissue. The 
optical properties most relevant for optical imaging include the absorption coefficient, scattering 
coefficient, and anisotropy factor. Absorption, or attenuation, of light is due to the conversion of 
electromagnetic energy into internal energy of the absorber. The absorption coefficient (µa [cm-





is typically 0.01-1cm-1. The attenuation light depends on the tissue chromophores and their 
concentrations. For a tissue composed of ! absorbing chromophores, the total absorption of the 
tissue at a given wavelength λ can be described by:  
 "#,% = ∑ (),%*)+),-  (1-1) 
where (),% is the wavelength-dependent molar extinction coefficient for each chromophore, and 
*) is the concentration of the .-th chromophore. Since (),% is known, it is possible obtain the 
concentrations of each optically absorbing chromophore *)  by measuring the absorption 
coefficient at ! wavelengths and solving the system of equations. The primary absorbers inside 
tissues in the visible or NIR wavelength range are HbO2, Hb, water (H2O), and fat. Thus, diffuse 
optical imaging is particularly well-suited to provide information about blood and its 
oxygenation. The absorption coefficient is measured according to the Beer-Lambert Law which 
states that the measured intensity of light / that has traveled through a layer of material with 
thickness 01 is related to the incident light intensity /2 according to the inverse exponential 
power law: 
 / = /2345678 (1-2) 
Light is also elastically scattered by organelles in tissue due to random spatial variations in tissue 
density, refractive index and dielectric constant. A photon undergoes multiple scattering events 
as it propagates through tissue. Scattering is characterized by the wavelength-dependent 
scattering coefficient (µs [cm-1]), which represents the probability per unit length of a photon 
being scattered.   
The anisotropy factor (g) represents the degree of directionality at which light is scattered 





positive and negative one, −1 ≤ < ≤ 1 and. A negative g indicates a backward scattering 
medium and a positive g indicates a forward scattering medium. In the visible and NIR range, 
most biological tissues are strongly forward scattering with < > 0.9. To simplify directional 
effects the reduced scattering coefficient (µs’ [cm-1]) is often used and is defined by: 
 "AB = "A(1 − <) (1-3) 
In biological tissues, the µs’ is typically 10-100cm-1.  
1.3.1.2 Reconstruction of Hb and HbO2 Concentrations 
By gathering data at different wavelengths, the chromophore concentrations [Hb] and [HbO2] 
can be derived using model based iterative reconstruction schemes [127-129]. First, a light 
propagation model is used to predict the measurement data based on the distribution of optical 
properties of the tissue [130-134]. Then, a scalar objective function evaluates the difference 
between the measured and predicted data. Finally, the distribution of optical properties is 
updated to reduce the objective function error. These steps are repeated in an iterative process 
that minimizes the objective function error while updating the distribution of optical properties.  
For this work, the light propagation model used is the diffusion approximation (DA) to 
the radiative transfer equation (RTE). The RTE is the most accurate and deterministic model of 
light propagation using the law of conservation of energy due to absorption and scattering, but is 
computationally expensive. The DA simplifies the RTE by assuming that most of the light is 
diffuse by the time it reaches the boundaries. Specifically, the DA assumes that the scattering is 
isotropic, the scattering length 1 "A⁄  is small compared to the photon propagation distance and 
that the reduced scattering coefficient is much larger than the absorption coefficient, "AB ≫ "#, 





Radiance G(H,Ω) is the light intensity at a spatial position H [cm] and solid angle Ω [sr] 
direction in units of [W/cm2/sr], The diffusion approximation is given by: 
 −∇ ∙ K(H)∇L(H) + "#(H)L(H) = N(H) (1-4) 
where N(H) [W/cm3] is the isotropic source function, L(H) [W/cm2] is the energy fluence rate, 
and K is the diffusion coefficient. L(H) and K are given by: 
 L(H) = ∫ G(H,Ω)0Ω	QR  (1-5) 
 K = -
ST56U5VWX
 (1-6) 
The boundary condition is given by L − 2Z[\⃑ ∙ ^⃑ = 0, where [\⃑  denotes the surface normal vector 
pointing outward, Z accounts for the refractive mismatch at the air-tissue interface, and the 
photon current is given by: 
 ^⃑(H) = ∫ ΩG(H,Ω)0Ω	QR ≅ −K(H)∇L(H) (1-7) 
The optical properties "# and "AB  at each wavelength can be obtained by fitting the analytic 
solution to the measured values of reflectance `(0)  using gradient-based approaches to 
minimize the error in the least squares fit. Then the chromophore concentrations (e.g. [HbO2] 
and [Hb]) can be obtained from "# and "AB  at multiple wavelengths according to Equation 1-1. A 
multispectral method inverse model can directly recover the chromophore concentrations by 
using data from all wavelengths simultaneously [135], instead of the two-step method described 
above.  
Functional properties can also be extracted by dynamic diffuse optical imaging (DOI) of 
the change in hemoglobin concentrations imposed on the system. Fast imaging is accomplished 





tissue and the amplitude difference in the detected light is used to reconstruct the relative 
changes in chromophore concentrations.  
1.3.2 Diffuse Optical Spectroscopy (DOS) of PAD 
In diffuse optical spectroscopy (DOS), localized topographic regions of tissue are probed in a 
reflectance-based geometry. In a reflectance-based geometry, sources and detectors are located 
on the same face of the tissue surface. DOS has been applied to diagnosing [136-142] and 
monitoring PAD [136, 140]. DOS has been used to surveille muscle oxygenation in the calf 
[143]. 
DOS has also been used to study exercise physiology by examining oxygenation of calf 
muscles before, during, and after exercise [144-146]. Exercise studies have provided insight to 
how oxidative metabolism increases and decrease during plantar flexion and exercise. These 
studies have also provided information about the regional changes in oxygen availability during 
dynamic exercise. Such studies provide a foundation to study perfusion in the lower extremities 
for diseases such as peripheral artery disease (PAD). Intra-operative use of DOS has also been 
used during revascularization procedures [147, 148].  
However, dynamic DOS measurements do not provide the physician with a cross-sectional 
image hemodynamics, but simply a time trace of the hemodynamics at a localized measurement 
location. This is complicated by the sensitivity of DOS measurements to the location of the 
probe. Diffuse optical tomographic measurements are less dependent on location and can provide 





1.3.3 Diffuse Optical Tomography (DOT) of PAD 
In diffuse optical tomography (DOT), tomographic slices or volumes of tissue are investigated 
using additional sources and detectors to probe the tissue from various projections. DOT utilizes 
transmission-based geometries in addition to reflection-based geometries [149-152]. Because 
larger volumes of tissue are probed from multiple locations, DOT is less sensitive to location 
than DOS and can produce spatially resolved images of hemoglobin concentrations [Hb] and 
[HbO2] in the tissue if the geometry of the imaging medium is known [153-162]. 
We have previously shown that DOT has strong potential as a method for the diagnosis 
and evaluation of PAD [163, 164]. It can measure physiologically important parameters about 
the peripheral arterial system by measuring the hemodynamics in the foot during a venous 
occlusion at the thigh. Forty subjects (10 non-diabetic patients with PAD, 10 diabetic patients 
with PAD, and 20 healthy volunteers) were enrolled in a diagnostic pilot study. The DOT system 
was capable of quantifying the blood volume changes at the mid-metatarsal level of the foot 
during a thigh cuff occlusion and outputting diagnostic parameters, like change in hemoglobin 
concentration, which provided a sensitivity of 86.67% and a specificity of 68.42% regardless of 
diabetic co-morbidities.  
In DOT foot imaging for PAD, the change in hemoglobin concentration during a venous 
occlusion at the thigh is used to assess arterial disease in the leg. Figure 1-6 shows the percent 
change in total hemoglobin concentrations during a 5-phase venous occlusion protocol: (1) 
baseline, (2) 60mmHg pressure cuff, (3) recovery, (4) 120mmHg pressure cuff, (5) recovery. 
During the venous occlusion, the outflow of blood from the leg is blocked while the arterial 
inflow of blood is unaltered. This causes the total hemoglobin concentration ([HbT]) in the foot 





venous occlusion is much lower for PAD patients than healthy patients, indicative of arterial 
disease. This measure also correlated with the ABI measure in the non-diabetic PAD population, 
indicating that DOT has the ability to assess the severity of arterial disease, even within diabetic 
patients with calcified arteries. Thus, DOT measures blood perfusion and is independent of 
arterial calcification, making it ideal for detecting and monitoring PAD.  
 
Figure 1-6. Percent change in total hemoglobin concentration during a 5-phase venous 
occlusion protocol: (1) baseline, (2) 60mmHg pressure cuff, (3) recovery, (4) 120mmHg 
pressure cuff, (5) recovery. Δ[HbT] at the end of the venous occlusions in phases 2 and 4 
are much lower for PAD patients than healthy patients, indicating a problem with arterial 
blood flow to the foot. 
In addition, DOT was capable of providing images revealing under-perfused areas within a 
cross-section of the foot (see Figure 1-7, left). This could potentially help in guiding and 
monitoring surgical interventions. Three angiosomes are captured within the cross-section at the 
mid-metatarsal level of the foot: the medial plantar artery (MPA) angiosome, the lateral plantar 
artery (LPA) angiosome, and the dorsalis pedis artery (DPA) angiosome. Angiosomes with 
under-perfusion in PAD patients could be identified when the ∆[HbT] during the venous 
occlusion was looked at separately for each angiosome. This information could potentially guide 





through three different arteries, the anterior tibial artery (ATA), the (posterior tibial artery) PTA 
or the peroneal artery (PA). Looking at the average responses within the angiosomes, they can 
make a more informed decision on which artery they should use to intervene.  
 
Figure 1-7. 2D reconstruction of the change in hemoglobin concentration in a coronal 
cross section of the foot (left) and DDOT source and detector fiber placement around the 
mid-metatarsal level of the foot (right) 
 
Our DOT imaging resulted in very useful 2D images of blood perfusion through the vessels that 
line the top and bottom of the foot using a fiber-based system. Fiber-based systems are routinely 
used in DOT due to several advantages including the flexibility of fiber-based systems to easily 
capture both reflection and transmission measurements without additional optics since the fibers 
can be placed anywhere. In addition, fiber-based systems have a large dynamic range (>150dB) 
because each fiber maintains its own dynamic range and is not directly affected by the intensities 
at other fibers.  
1.4 Summary of Background and Motivation 
The reduction of blood flow to the lower extremities in PAD can lead to intermittent claudication 








many patients are asymptomatic (without any leg pain) and present in an advanced stage of PAD 
with ulcers. PAD patients with CLI are at a high risk of amputation. Diabetes and end-stage 
kidney disease complicates PAD. In addition, PAD overlaps with many other cardiovascular 
diseases and timely diagnosis is crucial. Treatment options including lifestyle modification, risk 
factor treatment, medical intervention aim to manage the disease and prevent its progression and 
mitigate critical cardiovascular events. Revascularization is the crutch of treatment for PAD 
patients who have failed to manage the disease with lifestyle modification and medical 
management. Revascularization procedures are the last hope to mitigate tissue loss and 
amputation by enabling reperfusion the ischemic tissue.  
Over 100,000 PAD related surgeries are performed in the United States annually. This 
includes percutaneous endovascular revascularizations (balloon angioplasty, stenting, 
atherectomy) and surgical revascularizations (bypass surgery). These interventions aim to 
increase the blood perfusion in the foot. Clinical evaluations of bypass versus endovascular 
revascularizations, stratified by patient populations (diabetic, end-stage renal disease, IC vs CLI, 
wound healing vs rest pain or claudication, wound stratification) is an ongoing area of research 
to determine restenosis and patency rates of these surgeries. These patients are at risk for 
developing new or recurrent lesions, which underscores the need for monitoring. In addition to 
the importance of hemodynamic assessment for diagnosis, assessment for treatment and 
management direction and follow-up assessment are equally important.  
While many of these procedures are successful, up to 50% of all patients require a second 
intervention within 12 months and up to 15% of patients do not see clinical improvements 
despite technically successful revascularizations and patency. These patients still require a 





revascularization (DR) has gained attention over the past decade for improving the outcomes of 
these interventions. However, research on DR is fairly young and most studies are retrospective 
have been limited in numbers. Although these studies support the usefulness of DR, it is still 
debated and its mechanism is still unknown partially due to the lack of an appropriate measure of 
perfusion.  
Hemodynamic assessment to direct revascularization, aid in revascularization 
intraoperatively, evaluate or predict revascularization success post-operatively, and to monitor 
perfusion in ongoing follow-up are important in ensuring optimal outcomes from the 
revascularization. Monitoring techniques to evaluate whether the revascularization was 
successful based on quantitative perfusion assessment may identify patients at risk for poor 
outcomes. These patients can receive additional management to reduce secondary 
revascularization, mitigate adverse outcomes, and minimize economic burden [165, 166]. These 
measures could also lead to a better understanding of treatment mechanisms and better direction 
of future revascularizations and improve outcomes.  
However, accurate hemodynamic assessment is challenging with current evaluation 
methods, especially in the CLI population and diabetic PAD population [32, 33, 167]. The ABI 
is not useful in patients with calcified arteries such as diabetics. Other imaging methods such as 
DUS and angiography are useful in revealing anatomic obstructions, but do not directly measure 
blood perfusion in the foot. Angiographic methods also utilize contrast agents which is 
contraindicated in diabetics and ESRD patients. This patient population amounts to up to 41% of 
the PAD population [168, 169]. Evaluation of PAD in this population is hampered by the lack of 
contrast-free and non-ionizing imaging methods that assess the blood perfusion in the distal 





undergo surgery and are the in need of post-surgical monitoring. There is a need for a functional 
imaging method that provides direct measures of foot perfusion without the use of exogenous 
contrast agents or ionizing radiation [170, 171].  
Diffuse optical imaging (DOI) may provide a cost-effective and non-invasive solution to 
this problem. DOI is sensitive to hemoglobin and vascular changes. We have previously shown 
that dynamic diffuse optical tomography (DOT) has great potential for detecting PAD [2, 3]. 
However, the system employed a measurement head that brought optical fibers in contact with 
the patient’s foot. Contact-based DOT systems are not well suited for the clinical setting because 
fiber placement is cumbersome and tissue surfaces affected by ulceration and gangrene should be 
avoided.  
This work aims to evaluate the use of DOS in monitoring revascularization procedures 
and to develop novel DOT instrumentation for evaluating foot perfusion. By monitoring 
revascularization procedures with DOS, we hope to demonstrate that DOS perfusion 
measurements are useful in monitoring and predicting revascularization outcomes and in 
improving our understanding of the physiological mechanisms of angiosome-directed 
revascularization. Development of a novel contact-free multi-view CW DOT system for 





2 Monitoring PAD Revascularizations with DOS 
Recent advances in revascularization technologies has improved the treatment of PAD patients 
with IC and CLI patients. However, despite these advances and obtaining patent flow to the foot, 
up to 15% of patients do not experience clinical improvement. There is a need directly measure 
perfusion to measure the revascularization response. Current methods to monitor 
revascularizations including PVR and arterial DUS measure patency and find new lesions. ABI 
attempts to measure the hemodynamics, but it is not reliable in a large percentage of patients.  
The ability of DOS to measure perfusion in the foot without the use of ionizing radiation or 
exogenous contrast agents makes it an attractive solution to this problem. Previous studies have 
shown the promise of DOS in diagnosing PAD, but it has not yet been utilized in monitoring 
PAD revascularizations. We investigate the utility of diffuse optical spectroscopy (DOS) in 
monitoring PAD revascularizations in an ongoing 100-patient study. The goal of the study is to 
determine if DOS can predict outcomes of revascularization procedures and shed light on the 
mechanisms of successful interventions in the context of the angiosome concept. This has the 
potential to help improve patient outcomes and reduce the healthcare burden.  
2.1 Study Overview and Methods 
2.1.1 Study Protocol 
In a 100-patient longitudinal study, we monitor PAD patients undergoing lower extremity 
revascularization procedures with DOS measurements. The study protocol is approved by the 
Columbia University Medical Center Institutional Review Board (protocol #IRB-AAAK6702). 





no other restrictions in the inclusion or exclusion criteria. Additionally, the results of the study 
are not shared with the participants and do not affect their standard of care. A summary of the 
protocol is shown in Figure 2-1.  
 
 
Figure 2-1: Targeted data collection time points for the study 
 
Patients who provide informed consent to participate in the study have DOS measurements 
obtained prior to the angiogram procedure, after the procedure, and at follow-up visits targeted at 
1-month, 3-month, 6-month, and 12-month time points. The clinical measures of the peripheral 
vasculature are collected from patient medical records for the most recent time point before the 
angiogram, and at the follow-up visits up to a year after the angiogram. These clinical measures 
include lower extremity ABI measurements, PVR classifications, arterial duplex exams, bypass 
graft surveillance exams, and iliac artery duplex exams. At follow-up visits, clinical measures 
were only completed if clinically indicated and are not always available to correlate with the 
DOS measures. Furthermore, patients who had a diagnostic angiogram (i.e. did not get an 
endovascular intervention at the same time as the angiogram) did not stay on the study and were 
not measured at the follow-up time points. We also collect the age, gender, chief complaint, 
relevant previous medical history, angiogram findings, intervention types and locations, and 
other peripheral arterial disease risk factors for all enrolled patients. 
1mo 3mo 6mo 12moAngiogram






2.1.2 DOS Measurements 
2.1.2.1 DOS Instrumentation 
An extension of a previously described DOS system [172] is used to collect point-based 
measurements of the vascular dynamics during a venous cuff occlusion in the lower extremity. 
The system is a portable 4-channel CW DOS system with each channel consisting of four source 
wavelengths (5mW at 780nm, 808nm, 850nm, 904nm) and two silicon photodiode detectors. The 
sources are modulated at 5kHz, time-series multiplexed (one wavelength illumination at a time) 
and detected by the two photodetectors using lock-in detection. This scheme is described in more 
detail in previous work by our group [172]. Three patch channels (channels 1 – 3) are configured 
in reflectance geometry with source-detector distances of 10-19 mm and 16-25 mm for the two 
detectors, respectively. Channel 4 is a toe clip with the sources and detectors arranged in 
transmission geometry. The system collects data from all four channels at approximately 2.6Hz. 
An image of the system is shown in Figure 2-2. 
 





2.1.2.2 DOS Measurement Locations 
The 4 channels are placed around the lower extremity to measure the hemodynamics in the 
different angiosomes that are fed by 3 major tibial arteries (posterior tibial artery, PTA; peroneal 
artery, PERA; and anterior tibial artery, ATA). The first channel is placed over the ATA 
angiosome on the top of the foot. The second channel is placed on the bottom of the foot over the 
LPA angiosome (fed by the PTA). The fourth channel is placed on the toe and measures the 
MPA angiosome (also fed by the PTA). The toe is also fed by the dorsal pedis artery (DPA, fed 
by the ATA). Thus, while we refer to channel 4 as the ‘MPA angiosome’, the channel measures a 
combination of the ATA and the LPA.  For the first 29 subjects, the third channel is placed on 
the calf muscle over the PTA angiosome. This was initially done because many groups have 
performed DOS exercise oxygenation studies on the calf muscle. For the remaining subjects, the 
third patch is placed over the PERA angiosome by the outer ankle. This was done to ensure we 
measured all angiosomes and remove duplicated measurements of the angiosomes fed by the 
posterior tibial artery PTA. Figure 2-3 shows a diagram of measurement locations in relation to 
the angiosomes of the lower limb. The patches are fixed to the foot and using Velcro straps. 
Photos of the measurement locations are taken for documentation. The photos are also used at 
follow-up time points to match the measurement location with previous time-points. While the 
patch and toe clip placements described were attempted in all patients, the patches were either 







Figure 2-3: DOS channel placement locations according to the angiosome theory 
 
2.1.2.3 DOS Imaging Protocol 
The dynamic imaging protocol consists of 5 phases: (1) 1-minute baseline rest, (2) 1-minute 
60mmHg venous occlusion, (3) 1-minute recovery, (4) 1-minute 100mmHg venous occlusion, 
and (5) 1-minute recovery. This protocol and the resulting raw signals from the 8 source-detector 
pairs of a single channel (relative to baseline) are shown in Figure 2-4. 
During the venous occlusion, a pneumatic cuff placed around the thigh is inflated. These 
pressures are meant to compress the veins such that the venous return of blood from the lower 
extremity is blocked, while leaving the arterial flow to the limb unaffected. During the occlusion, 
the blood pools in the lower extremity. Consequently, more light is absorbed and the detected 
light decreases. This decrease is observed during the occlusion in the signal intensity traces in 
Figure 2-4. The hemodynamic changes to the during the occlusion reveals information on the 





diagnose PAD. The protocol is much more comfortable than the higher pressures required to 
induce arterial occlusions, while still revealing information about the arterial vasculature.  
 
 
Figure 2-4: DOS imaging protocol and resulting relative raw signal intensities from the 
eight source-detector pairs 
 
The five-minute occlusion protocol is repeated twice (two trials) to ensure a quality signal is 
obtained. For example, some trials contain significant motion artifact. If a quality signal is not 
obtained on the first trial, the patches are sometimes moved or adjusted before the second trial.   
2.1.2.4 DOS Reconstruction 
The raw data from each channel is reconstructed to [HbO2] and [Hb] using a constrained 
spatially resolved spectroscopy algorithm using a diffusion approximation with a semi-infinite 
homogenous assumption. First, a 1D Gaussian filter was used on each source-detector signal to 





detector selection was completed based on these filtered signals. A semi-automatic source-
detector selection was utilized where a source-detector signal was excluded if: 
• The signal was too low 
o The signal had any recorded values < 0.05V 
o The median of the signal values was < 0.1V 
• The signal was saturated  
o The median of the signal was >2.9V 
• The signal was too noisy 
o The standard deviation of the signal was >0.04V 
In addition, the cross-correlation between the 8 source-detector pairs was also calculated. Signals 
with correlations <0.3 with more than 5 other source-detector signals were excluded. These 
excluded source detector pairs were manually reviewed and adjusted. For example, adjustments 
were made to exclude source-detector signals that had a linear drift in an opposite direction than 
other source-detector signals. 
The original system and reconstruction was intended to reconstruct absolute [Hb], 
[HbO2], and scattering using the four wavelengths of data and calibration measurements of an 
optical phantom. However, in this study we are most concerned with the dynamic changes during 
the venous occlusion, and absolute chromophore concentrations are not necessary. For the scope 
of this work, the reconstruction algorithm was adjusted accordingly and relative reconstructions 
were obtained for [Hb] and [HbO2] concentrations assuming constant scattering. 
 The forward prediction was generated assuming a semi-infinite homogenous medium 
with a [HbO2] of 23.4306 µM, [Hb] of 14.6874 µM, and a µs’ derived from µs’ = A(a)-b with A = 





reference and scaled by the forward prediction to obtain a normalized data set. The normalized 
data was used to solve the inverse reconstruction problem for [Hb] and [HbO2]. Relative 
changes in [HbO2] and [Hb] relative to the initial frame. All values represent the change in 
concentrations (i.e. ∆[HbO2]% and ∆[Hb]%). 
The diffuse reflectance measured at multiple locations on the tissue surface depends 
solely on the absorption coefficient "#, the reduced scattering coefficient "AB , and the source-
detector separation 0 . There is a closed-form analytic solution for the spatially resolved 
reflectance of a semi-infinite homogeneous medium given by [173]: 



























+ 0r; "eff = y3"#"AB  ; "{B = "# + "AB  (2-2) 
where Z is the internal reflection parameter accounting for the refractive index mismatch at the 
air-tissue interface [174]. The optical properties "# and "AB  at each wavelength can be obtained by 
fitting the analytic solution to the measured values of reflectance `(0) using gradient-based 
approaches to minimize the error in the least squares fit. Then the chromophore concentrations 
(e.g. [HbO2] and [Hb]) can be obtained from "# and "AB  at multiple wavelengths according to 
Equation 1-1. However, gradient-based approaches are highly sensitive to noise.  Instead, we 
minimize the objective function error by employing a multispectral evolutionary algorithm that 
utilizes data from all wavelengths simultaneously to directly reconstruct chromophore 





Briefly, evolution strategies imitate the principles of heredity in nature for inverse 
problems. In the evolution strategy, individuals that represent a wide range of potential solutions 
to the inverse solution (e.g. 1| = ([~Är], [~])|) form a population ÇÉ = (1-,… , 1Ö)É. The 
population can recombine and mutate to create offspring to form a new population. At each 
iteration, the individual offspring are evaluated with the objective function and only a the fittest 
of the offspring are selected as the population for the next iteration ÇÉU- = (1-,… , 1Ö)ÉU-. The 
solution to the inverse problem is identified once the objective function has reached an 
acceptably small value. This method is more robust and overcomes the sensitivity to the initial 
guess, local minima, and noise in gradient-based minimization methods.  
2.1.2.5 Feature Extraction 
The hemodynamics of a venous occlusion reveals information about the status of the arterial 
vasculature between the location the venous occlusion is applied and the measurement location. 
As discussed previously, the venous occlusion blocks the venous outflow of blood from the 
lower limb but leaves the arterial inflow of blood intact. In a healthy individual with good blood 
flow through the arteries, the blood will begin to accumulate in the veins and the vascular bed 
quickly and reach a saturation point earlier during a venous occlusion. In an individual with 
reduced blood flow through the arteries, the blood accumulates much slower during the venous 
occlusion. During the 1-minute occlusion, the saturation point may not be reached. To 
characterize these hemodynamic changes, various features from the DOS measurement traces 
can be extracted.  
 For the scope of this work, I look at the total hemoglobin concentration to represent the 





∆[HbT]% is derivred from the reconstructed relative ∆[HbO2]% and ∆[Hb]% time traces by 
simply adding the two together (∆[HbT]% = ∆[HbO2]% + ∆[Hb]%). From this ∆[HbT]%  trace, 
the start and end times of the occlusions are determined, any linear drift across the trace is 
removed, and various features are extracted from the occlusion traces.  
The time of the end of each occlusion is determined by detecting the peaks in the 
∆[HbT]% time trace. The general peak location for an occlusion is determined by looking at the 
1st and 2nd derivatives of the filtered raw data for all source detector pairs (up to 32 traces, a 
measurement trial contains 4 time traces for the 4 respective channels). The median time of the 
peaks across traces is considered the occlusion end time for that measurement trial. This results 
in two peaks per trial for the two occlusions. For each occlusion, the time of the end of the 
occlusion is adjusted by the looking for the maximum ∆[HbT]% in an 8 second window centered 
around the calculated peak for the trial. These occlusion end times are manually verified for 
accuracy and adjusted if necessary. The occlusion start times are defined as 60 seconds prior to 
the occlusion end times. Although it takes approximately 10 seconds to inflate the cuff manually, 
there is evidence that similar results are obtained as long as inflation to 40mmHg occurs within 4 
seconds [136]. Next, any linear signal drift in the time traces are removed. To do this, a linear fit 
to 4 points along the time trace is computed. The 4 points include the first frame, the frames at 
the start of each occlusion, and the last frame. The line from the linear fit is subtracted from the 
time trace.  
This results in two 1-minute occlusion traces per measurement trial. There are many ways 
to quantify each occlusion trace, including features from the relative ∆[HbT]% trace and features 
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where ∆[~å]%ôööõ{#g{  and ∆[~å]%ôööúÖ7 are the ∆[HbT]% curve values at the start and end 
of the occlusion, respectively, as defined above. For feature extraction, we consider the occlusion 
traces defined as the trace from occlusion start to occlusion end. The following features were 
extracted from relative and/or normalized occlusion traces, if indicated: 
1. Percent Change: This is calculated from the relative ∆[HbT]% curve as: 
 Çù = ∆[éèê]%ëííñóò
∆[éèê]%ëííñóò4∆[éèê]%ëííìb6ïb
 ( 2-4 )  
This represents the blood accumulation achieved by the end of the occlusion, and should 
be higher for healthy arteries and lower for diseased arteries.  
2. Rise Time and Normalized Rise Time: This feature is defined as the time in seconds 
between 10% and 80% of the occlusion trace start to end value. It represents how quickly 
the occlusion trace rises. We expect fast changes and a short rise time for healthy arteries. 
Slower blood flow would result in slower pooling and longer rise times.  
3. Pooling Delay and Normalized Pooling Delay: This is defined as the time in seconds to 
the start pooling. The start of pooling is defined as the time of 10% of the occlusion start 
to end value. This represents the time it takes for blood to start accumulating. In healthy 
arteries, we expect the pooling delay to be shorter with increased blood flow. With 
reduced blood flow, it would take longer for blood to start pooling and reach 10%. 
4. AUC and Normalized AUC: This is defined as the area under the occlusion curve and 





5. Normalized Pooling Rate (NPR): This is the average normalized ∆[HbT] during the 
occlusion divided by the 60s occlusion time. Larger NPR indicates better arterial inflow.  
The normalization process and the features extracted are summarized in Figure 2-5.  
 
 
Figure 2-5: Summary of features extracted from total hemoglobin occlusion traces 
 
The DOS system makes point-based measurements which is sensitive to the placement of the 
measurement probe. Specifically, the amplitude of the relative [HbT] changes for the occlusion 
can change drastically based on the location of the probe.  Consider a probe placed directly over 
a large vessel or vascular bed versus a probe placed over bone. The blood volume changes 
during a venous occlusion in the vessel or vascular bed would be fairly high in comparison to the 
bone. Thus, the actual amplitude changes in the relative [HbT] traces are not reliable measures 
for point-based measurements. The shape of the relative [HbT] changes during the occlusion are 





describe the shape and measures based on the determination of the 10% and 80% of the peak are 
sensitive to anomalies in the signals. Thus, for the scope of this analysis, I concentrate on the 
normalized pooling rate (NPR) as a single measure.  
2.1.2.6 Data Selection 
DOS measurements at each time point contains multiple trials. Each trial contains multiple 
occlusions. The first occlusion for each patient was utilized for this analysis. Previous work has 
shown that the percent change from the 60mmHg occlusion could distinguish between health and 
PAD patients. In some patients, a 100mmHg thigh cuff pressure induces a partial arterial 
occlusion. Furthermore, the effect of multiple sequential cuff occlusions is not yet well 
characterized for these DOS measurements. The effect is dependent on various uncontrolled 
factors.  
A single trial was selected for each patient based on the quality of the data.  For example, 
trials with artifacts or no visible response to the occlusion were excluded from the analysis. Since 
there may be an effect of sequential cuff occlusions in some patients, the same trial was selected 
for all time points for each patient, if possible. This results in a single occlusion trace and its 





2.2 Results: 51-Subject Pilot Analysis 
2.2.1 Patient Population 
In this ongoing study, 51 patients have been enrolled according to the study methods outlined 
above. Of these patients, 45% were female and 55% were male, 49% were smokers or former 
smokers, 66% were diagnosed with diabetes, 80% were diagnosed with hypertension, and 59% 
were diagnosed with hyperlipidemia. 55% of the patient population presented with chief 
complains of claudication. The other 45% presented with chief complaints of wounds. The 
average age of the patients at enrollment was 71.4 ± 12.6 years. The average body mass index 
(BMI) was 28.4 ± 5.7. Histograms of the patient age and BMI are show in Figure 2-6 and Figure 
2-7, respectively. A large percentage of patients (>56%) are overweight or obese. An additional 
13.7% have an ABI between 24 and 25, which is approaching overweight. We do not have BMI 
data for 17.7% of the study population. The demographic makeup included 10% Asian, 16% 
African American, 18% Hispanic, 53% not-Hispanic White, and 4% were unreported. 
Table 2-1: Patient population characteristics 
 Percent of Study 
Population 
Age 71.4 ± 12.6 years old 
Female 45% 
Male 55% 
Chief Complaint: Claudication 55% 











Figure 2-6: Histogram of patient age. Patients are largely distributed between 50 and 90 
years. 
 
Figure 2-7: Histogram of patient body mass index (BMI). Approximately 2% of patients 
are underweight (N=1), 23.5% are healthy (N=12), 33.3% are overweight (N=17), 23.5% 










All of the patients enrolled underwent a diagnostic angiogram. While 12 patients did not receive 
any intervention at the same time as the angiogram, 39 patients received at least one intervention 
at the same time as the angiogram. These interventions included angioplasty (N=32), angioplasty 
with a drug coated balloon (N=14), stent placement (N=14), drug eluting stent placement 
(N=12), atherectomy (N=6), endarterectomy (N=1), and bypass (N=3). These interventions are 
broken down by location in Table 2-2. Multiple interventions were sometimes done at the same 
location, i.e. an angioplasty and a stent to treat the same stenosis. A summary of the intervention 
locations is shown in Figure 2-8. Multiple interventions to treat the same location were counted 
only once. In addition to multiple interventions per location, patients sometimes received 
interventions on multiple vessels in the same surgery. Thus, the total number of intervention sites 
does not match the number of patients receiving an intervention. 
 
Figure 2-8: Breakdown of N=54 intervention locations for the 39 patients that received 
interventions. Patients sometimes received interventions in multiple locations in the same 





A total of 35 patients are off the study. This includes the 12 patients that did not undergo an 
intervention, 7 patients that have required a second intervention on the same leg within a year of 
the initial intervention, 6 that completed a follow-up at least 6-months post-intervention and did 
not require a second intervention within the year, 7 that were lost to follow-up, and 3 patients 
that are deceased. For patients who underwent an interventional angiography and have 
completed the study, we had approximately a 21% loss to follow-up of patients undergoing 
interventional angiography by the 3-month time point, which increased to 29% and 42% at the 6-
month and 11-month time points.  
Table 2-2: Table of interventions broken down by intervention location. Patients 
sometimes received multiple interventions for the same intervention site (i.e. angioplasty 
and stent).  
















EIA/CIA   7   1 
CFA 1 1     
SFA 6 8 7 6 2  
POPA 4 4   2  
TPT 2   2   
PTA 4      
PERA 4      
ATA 7   3 2  











Figure 2-9: Summary of the DOS measurement data collected at each potential time point 
(Pre-procedure, post-procedure, and 1 to 12-month follow-ups).  
 
2.2.2 Case Studies 
2.2.2.1 Revascularization of a Previous Bypass Graft Anastomosis Stenosis 
Patient S44 is an 85-year-old non-diabetic female with a history of hypertension, edema, and a 
previous right leg femoral-peroneal bypass. The patient presented for a 4-month follow-up post 
bypass with no new symptoms and severely decreased perfusion according to ABI (DP: 0.55, 
PT: 0.59) and PVR measures. A bypass graft surveillance duplex revealed a severe <80% 
stenosis of the distal anastomosis of the bypass graft. The patient underwent a right lower 
extremity angiogram and an angioplasty of the right peroneal artery bypass anastomosis. The 






Figure 2-10: Normalized occlusion curves of [HbT] for patient S44 at pre- (blue), post- 
(green), and 1-month (red) time points. Patient S44 received an angioplasty of a previous 
bypass graft anastomosis, but the anastomosis had restenosis by within the first month. 
 DOS measurements were acquired pre-operatively before the intervention, post-
operatively, and at the first follow-up, shown in Figure 2-10. We were unable to obtain good 
DOS measurements for the toe clip at the post-op time point. The DOS measurements the 
capture the improvements from the intervention. The green post-operative measurements have a 
much different shape than the pre-op measurements in blue. The post-op measurements show the 
total hemoglobin pooling much earlier than in the other time points. The post-op measurements 
also reach a saturation level, where no more blood pools.  
By the first follow-up 3 weeks after the surgery, the bypass graft surveillance revealed an 
early hemodynamically significant stenosis (75-99%) of the distal anastomosis. The ABI (DP: 






Figure 2-11: Plot of the change in normalized pooling rate (relative to pre-op) for S44 
where ‘-1’ is the pre-op time point, ‘0’ is the post-op time point, and ‘1’ is the 1-mo 
follow-up. 
Figure 2-11 shows the change in normalized pooling rate (NPR) relative to the pre-op over time. 
Notably, the largest post-op change in NPR is seen in the PERA patch (purple), which was 
directly opened by the angioplasty. The DOS measurements also captured the early restenosis of 
the bypass graft. This highlights the potential utility of the system. This system may be useful for 
at home monitoring of this at-risk patient population. 
2.2.2.2 Improved Claudication 11-months Post-Revascularization 
Patient S9 is an 87-year-old female previous smoker that presented with complaints of right leg 
claudication and a history of varicose veins, hyperlipidemia, and PAD. The NIFS indicated 
moderately decreased perfusion (ABI: 0.82 DP, 0.65 PT). The duplex exam showed a possible 
occlusion of the right TPT, moderate stenosis of the distal SFA and proximal ATA. The CFA, 
DFA, POPA, PTA, and PERA were patent. She was scheduled for a right lower extremity 
angiogram with possible angioplasty, stent, and atherectomy. The angiography revealed patent 
CFA, DFA, POPA, ATA, and PERA. However, a high-grade stenosis in the distal SFA and an 





angioplasty. The patient returned for a 1-week follow-up reporting improvement with 
claudication. The patient reported being able to walk 5-6 blocks, but clinical measures were 
obtained. 
 The patient returned for a 3-month follow-up visit and reported doing well. She was able 
to walk >10 blocks (or without limit) compared to 1-2 blocks prior to the procedure. The duplex 
exam showed occlusions in the PTA and PERA, a mild stenosis in the distal POPA, moderate 
stenosis of the ATA. The right CFA, PFA, and SFA were patent. The duplex also noted multiple 
collaterals branching off the runoffs, and moderate to heavy atherosclerosis throughout. While 
the duplex noted additional occlusions in the leg, the patient’s symptoms were resolved. 
 The patient returned 11-months post-op with complaints of claudication on her 
contralateral (left) leg after 1 block of walking. The right leg remained asymptomatic. The NIFs 
revealed mildly decreased perfusion of the RLE. The right leg arterial duplex showed an 
occlusion of the TPT, mid PTA, and PERA, a moderate stenosis of the distal SFA, and a severe 
stenosis of the mid ATA. The CFA, DFA, and POPA were patent. The ABI measures improved 
slightly from the 3-month follow up (0.77 to 0.82 at the DP, and 0.68 to 0.77 at the PT). The 






Figure 2-12: Normalized occlusion curves of [HbT] for patient S9 at pre- (blue), post- 
(green), 1-month (red), and 11-month (purple) time points.  
DOS measurements were obtained for the 1-month and 11-month follow-up time points. The 
normalized [HbT] occlusion curves are shown in Figure 2-12. No good pre-op data was obtained 
for the PTA channel, but there is an improvement on the ATA, LPA, and MPA channels at the 
post-op time point (green curves relative to blue curves). By the 1-month follow-up the, the DOS 
measurements show even further improvement. This can be seen in a plot of the NPR measures 
relative to pre-op in Figure 2-13. This improvement is likely due to the development of 
collaterals.  The improvement is mostly maintained in the ATA and the MPA though the 11-
month time point. The LPA shows some decrease at 11-months. This likely reflects the untreated 
PTA. The post-op increase in the LPA is a result of flow between the dorsal pedis artery (DPA, 





as the patient developed mild occlusions in the POPA and TPT arteries at the 3-month time 
point. In this case study, we demonstrate the ability of the DOS measurements to follow-a patient 
whose symptoms resolved and remained in good condition 1-year post-intervention. The increase 
in the perfusion measures at the first follow-up may be a good indicator of the outcome. 
 
Figure 2-13: Plot of the change in normalized pooling rate (relative to pre-op) for S9 
where ‘-1’ is the pre-op time point, ‘0’ is the post-op time point, ‘1’-‘11’ are the follow-
up months. 
It is worth noting the differences in the arterial duplex exams. The exams were done by different 
people and the findings change slightly for each exam. This is not surprising, since the arterial 
duplex exam of below-the-knee arteries is difficult and known to be operator dependent. 
2.2.2.3 Second Revascularization Required 11-months Post-Revascularization 
Patient S2, a 58-year-old male smoker, presented with right foot pain and a history of diabetes, 





amputation. The patient also developed a great toe redness and osteomyelitis. The ABI values 
showed normal readings (ABI-DP: 1.03, PT: 0.99). PVR waveforms revealed moderately 
abnormal perfusion. The right arterial duplex revealed a diseased right ATA and PTA. The 
patient was scheduled for a RLE angiogram with possible angioplasty, stent, and atherectomy. 
The angiogram revealed patent CFS, DFA, and SFA with mild to moderate calcification. The 
POPA had a short segment high grade stenosis in the mid segment but was otherwise patent. The 
TPT also had a long segment high-grade stenosis extending to the proximal PERA. The 
remainder of the PERA artery was patent. The PTA was occluded proximally but reconstituted in 
the mid-calf. The ATA was occluded throughout. The long segment stenosis in the TPT and the 
proximal PERA was treated by angioplasty. The proximal occlusion in the PTA was also treated 
with angioplasty. The short segment stenosis in the POPA was treated with angioplasty and DCB 
angioplasty.  
By the first follow-up at 3-weeks, the ABI (ABI-DP: 1.01, PT: 1.07) and PVR indicated 
normal perfusion at the ankle. The duplex measures also indicated an overall improvement with 
mild stenosis in the proximal DFA not noted previously. The duplex also noted severe stenosis of 
the mid and distal SFA not previously noted. However, the treated POPA, PTA, and PERA were 
patent. The ATA remained occluded.  
The DOS measures for the pre-, post, 1-month (3 weeks), and 7-month follow-up time 
points were collected. We see an improvement in the perfusion on all channels post-op (green 
curves) versus pre-op (blue curves) in Figure 2-14. However, this level of improvement is not 
maintained at the 1-month follow-up (red curves). The decline in perfusion at the 1-month time-
point may be associated with the new occlusions in the mid and distal SFA. Though, these 






Figure 2-14: Normalized occlusion curves of [HbT] for patient S2 at pre- (blue), post- 
(green), 1-month (red), and 7-month (purple) time points.  
 
The patient returned for a 5-month follow-up. The ABI measures remained within normal range 
(ABI-DP: 1.28 DP, PT: 1.18) and the PVR waveforms were mildly abnormal. The arterial duplex 
revealed similar findings as the previous study (but the severe stenosis in the SFA was described 
as a diffused stenosis of the SFA). The duplex measures also found alternating segments of flow 
and low flow in the PTA, but otherwise patent POPA, PTA, and PERA.  
 The patient returned for a 7-month follow-up where the ABI values were falsely elevated 
(ABI-DP: 1.96, PT: 1.99). The PVR waveforms showed some decreased perfusion at the ankle 
from the 5-month follow-up, with moderately abnormal waveforms at the metatarsal level. The 





cellulitis with his primary care doctor. He also has right plantar pain and knee pain with walking. 
The patient was considered stable and advised to return to the office in 6 months.  
 
Figure 2-15: Plot of the change in normalized pooling rate (relative to pre-op) for S2 
where ‘-1’ is the pre-op time point, ‘0’ is the post-op time point, ‘1’-‘7’ are the follow-up 
months. 
 
The DOS measures at the 7-month time point reveal decreased perfusion (Figure 2-15) across all 
angiosome channels. There is a sharp decrease in the NPR measures at the first follow-up time 
point, coinciding with the severe mid and distal SFA occlusion. The NPR measure further 
decreases by the 7-month time point, but are not quite as low as pre-op time point. While the 
perfusion measures show a large decrease by the 7-month time point, the patient does not yet 






11-months post-revascularization, the patient presented with decreased pedal pulses and 
claudication limiting his walking to 2-3 blocks. The arterial duplex exam revealed moderate 
stenosis of the DFA and mid SFA (similar to the 3-month time point). The CFA, POPA, PTA, 
and PERA were patent. The patient was scheduled for RLE angiogram with possible angioplasty, 
possible stent, and possible atherectomy. The angiogram revealed a long segment severe stenosis 
in the SFA with calcification. The PTA was occluded proximally and reconstitutes mid-calf. The 
ATA was occluded throughout. The operator-dependency of the arterial duplex findings is also 
noted in this patient. 
 In this case study, the DOS measures demonstrate the ability to capture the decrease in 
perfusion for a patient that ended up requiring a second revascularization procedure. The major 
decrease in perfusion was noted at the first follow-up in which a new severe stenosis of the SFA 
was discovered on the arterial duplex exam. Both the ABI and PVR measures indicated normal 
perfusion at the first follow-up. This may indicate that the ABI and PVR measures may not be 
able to discern the perfusion levels at the foot. The NPR perfusion measure remained low until 
the patient developed claudication at 11-months. The PVR waveforms were mildly abnormal at 5 
months, and moderately abnormal at 7 months. Once the patient developed symptoms, the SFA 
stenosis was treated. This diabetic patient’s ABI measures were normal at the first presentation 
(though probably still falsely elevated). However, over the next several months, the ABI 
measures increased and were falsely elevated by 7-months.  
2.2.2.4 Non-Healing Ulcer with Reduced Perfusion 
Patient S11 is a 68-year-old male with a prior medical history of diabetes, hypertension, 





prior. The patient presented for the evaluation of a chronic right foot plantar ulcer. The NIFS 
showed a mild to moderate arterial insufficiency (ABI-DP: 0.66, PT: 0.82), while the arterial 
duplex revealed a severe mid-SFA stenosis. The patient was scheduled for a right lower 
extremity angiogram with a possible atherectomy, angioplasty, and stent. The patient was 
hydrated pre- and post-procedure for renal protection and monitoring potassium levels. The CO2 
angiogram revealed a long segment high grade stenosis in the distal SFA with moderate 
calcification. The PTA was found diseased but patent.   The high-grade stenosis in the SFA was 
treated with angioplasty, DCB, and a drug-eluting stent. 
 
Figure 2-16: Normalized occlusion curves of [HbT] for patient S11 at pre- (blue), post- 
(green), 1-month (red), and 2-month (purple) time points. 
The DOS curves are shown in Figure 2-16. There is an improvement post-op, but there is a 
significant decrease in the NPR measures (Figure 2-17) by the first follow-up at 2-weeks (noted 





that his leg felt better. The ABI measures revealed mild to moderate decrease in perfusion (ABI-
DP: 0.74, PT: 0.71). However, an arterial duplex revealed an occlusion in the proximal SFA. The 
would remained open under wound care with his podiatrist. At a 2-month follow-up, the patient 
presented with the same wound which he did not think was healing. The patient was referred to 
another podiatrist to continue would care. In this case, the patient’s wounds were not healing 
quickly by the 2nd month, and the perfusion measured by DOS had declined by the first 2-weeks 
post-intervention. The LPA and MPA had the largest decrease in perfusion, which coincides with 
the location of the patient’s ulcer (plantar foot wound). The wound may not have healed due to 
decreased perfusion. However, since the patient was lost to follow-up, it’s not known if the 
wound healed despite the decreased perfusion.  
 
Figure 2-17: Plot of the change in normalized pooling rate (relative to pre-op) for S11 






2.2.2.5 Non-Healing Ulcer with Improved Perfusion 
Patient S6 presented as a 90-year-old female former smoker with a past medical history of 
diabetes, now controlled hypertension, varicose veins, venous insufficiency, and previous lower 
left extremity revascularization in the ATA, and healing ulcers in the right lower extremity. The 
patient presented with a 2-month old right medial malleolus foot ulcer. The vascular imaging 
showed occlusion of the right distal PTA and PERA, severe stenosis of the proximal ATA, and 
moderate stenosis of the distal ATA. The patient was scheduled for right lower extremity 
angiogram with possible atherectomy, angioplasty, and stent placement. The ATA stenosis was 
treated with atherectomy, angioplasty, and a drug eluting stent. The DOS curves are shown in 
Figure 2-18. 
 
Figure 2-18: Figure 2-19: Normalized occlusion curves of [HbT] for patient S6 at pre- 






The patient presented at a 3-week post-op follow-up with ulcer pain with pressure and leg 
swelling. The PVR revealed normal perfusion. The duplex exams revealed an improvement in 
the severe stenosis in the proximal ATA to moderate stenosis of the proximal and distal ATA. 
The ulcer was debrided at 3-weeks and 3-months. The patient’s wound care regiment included 
collagenase, unna boot, and hydrofera blue dressing. At 4 months, a moderate occlusion of the 
distal SFA was found on arterial duplex. The wound was found to be stable but not closing or 
healing and was referred to a foot and ankle doctor for evaluation for Epifix.  Epifix was applied 
at 5-months. The ulcer improved by 6-months but did not continue to heal. Ultimately a graft 
was necessary. No other vascular labs were ordered. In this patient, the perfusion in the foot was 
maintained for the most part according to the NPR measures (Figure 2-20). However, the ulcer 
did not heal despite the improvements in the perfusion.  
 
Figure 2-20: Plot of the change in normalized pooling rate (relative to pre-op) for S6 





2.2.3 Diagnostic vs. Interventional Angiography 
For the angiography, the patient is usually placed under mild sedation and systematically 
anticoagulated. A local anesthetic is used in the groin area over the femoral artery access point 
for percutaneous catheterization. Once access is established, catheters and guide wires are 
threaded through the lower extremity arterial system. Contrast agents are injected to visualize the 
flow in the arteries in the X-ray images. The surgeon can identify and characterize blockages 
from these images. Sometimes the blockages can be treated at the same time by angioplasty, 
stenting, or atherectomy. When this occurs, the procedure is known as interventional 
angiography. If the patient does not receive any treatment, the procedure is known as diagnostic 
angiography.  
2.2.3.1 Diagnostic Angiography 
We expect improvements in lower extremity perfusion for interventional angiography 
cases resulting from the treatment of blocked arteries. However, the vascular response to the 
angiogram is unknown and may have a short-term effect on the perfusion. For example, the 
drugs given in during the angiogram for sedation and anticoagulation may have an effect on the 
vascular system and an effect on the DOS measurements. Similarly, the use of the contrast 
agents, guide wires, and catheters in the vascular network may elicit a short-term vascular 
response. The DOS measures are collected pre-operatively before any sedation is given, and 1 to 
3 hours post-operatively in the recovery room. We hypothesize that if the catheters used and 
drugs administered during the angiogram have no effect on the DOS measurements, then there 
should be no difference in the pre- and post-operative measurements for diagnostic angiography 








Table 2-3: Patient population characteristics for diagnostic and interventional angiogram 
groups 
 Diagnostic Angiogram Interventional Angiogram 
Age 69.8 ± 7.4 years old 71.5 ± 14.1 years old 
Female 50% 42% 
Male 50% 58% 
Chief Complaint: Claudication 67% 50% 
Chief Complaint: Wounds 33% 50% 
Diabetes 50% 71% 
Hypertension 50% 79% 
Hyperlipidemia 67% 55% 
Smokers / Former Smokers 33% 53% 
 
Of the 51 patients in the study, 12 patients had a diagnostic angiogram. A summary of the 
diagnostic and interventional angiogram groups is described in Table 2-3. We collected post-
operative DOS measurements for 9 of these patients. We hypothesize that the pre- and post-
operative measurements will not be significantly different. For each pre- and post-operative 
measurement, there are up to 4 measurements of perfusion per patient, which correspond to the 
different angiosomes. That means there are up to 36 measurements in each of the groups. Several 
measurements were removed due to poor data quality leaving a sample size of N=31. Using a 
two-tailed paired t-test, we compared the pre- and post-operative measurements and found a 





measured from patient S32 showed a marked improvement. A plot of the changes in NPR are 
shown in Figure 2-21. The measurements from patient S32 are highlighted in red.  
 
Figure 2-21: Plot of the changes between pre- and post-operative DOS measurements in 
diagnostic angiography cases for the normalized pooling rate feature. The four channel 
measurements from patient S32 is highlighted in red. (p=0.25, without S32) 
Table 2-4: DOS feature statistics for diagnostic angiographies 
Feature 
Diagnostic Angiography p-value 
(without S32) Pre-Op 
(µ ± σ) 
Post-Op 
(µ ± σ) 
Normalized Pooling Rate (AU) 0.83 ± 0.15 0.89 ± 0.18 0.25 
Normalized AUC (AU) 29.2 ± 5.9 31.6 ± 6.5 0.38 
Normalized Rise Time (s) 34.1 ± 7.3 32.1 ± 7.6 0.93 
Percent Change (%) 23.5 ± 12.9 29.0 ± 20.1 0.064 
 
Excluding this patient from the measurements results in a non-significant difference (p=0.25). A 







2.2.3.2 Interventional Angiography 
=On the other hand, we do expect to see a significant difference for the interventional 
angiography cases. Of the 51 patients in the study, 39 patients underwent an interventional 
angiography. Using the same methods as the diagnostic angiography analysis, we compared the 
pre- and post-operative measurements and found a significant difference (p<0.0001) for NPR. A 
summary of the statistics for each feature is displayed in Table 2-5. There was a significant 
difference in all features except for the percent change. A plot of the changes in NPR are shown 
in Figure 2-22. 
This difference is confirmed by comparing the ABI pre- and post-operatively. The ABI 
measures were available for N=16 patients. A plot of the changes in ABI is shown in Figure 
2-23. While these measures are not time-matched to the DOS measures, the measures show a 
significant improvement (p=0.0017) for these patients.  
Table 2-5: DOS feature statistics for interventional angiographies 
Feature 
Interventional Angiography p-value 
(without S32) Pre-Op 
(µ ± σ) 
Post-Op 
(µ ± σ) 
Normalized Pooling Rate (AU) 0.81 ± 0.18 1.00 ± 0.21 < 0.0001* 
Normalized AUC (AU) 28.4 ± 7.4 36.3 ± 8.6 < 0.0001* 
Normalized Rise Time (s) 30.9 ± 6.6 23.5 ± 8.9 < 0.0001* 






Figure 2-22: Plot of the changes between pre- and post-operative DOS measurements in 
interventional angiography cases for the normalized pooling rate feature (p<0.0001*). 
 
Figure 2-23: Plot of the changes (p=0.0017*) between pre- and post-operative ABI 
measures for N=16 patients where the ABI was available.  
2.2.3.3 Diagnostic versus Interventional Angiogram  
Next, we compared the diagnostic angiogram group to the interventional angiogram group. We 
expect that there will be a larger difference in the interventional angiography group. A plot of the 






Figure 2-24. The changes for each group was compared in a one-tailed t-test, summarized in 
Table 2-2. There was a significant difference (p<0.005) in all features except for percent change. 
 
Figure 2-24: Plot of the changes in pre- and post-operative normalized pooling rate 
measures for diagnostic and interventional angiograms (p=0.0002*). A plot of each data 
point overlays the box plot. Each data-point represents the difference between a single 
channel pre- and post-operatively.  
In summary, we found that there is no effect of the angiogram itself on our DOS measures within 





that patient S32 was an outlier, more data is necessary. It is also worth noting that if the post-
operative measurements are taken sooner, or even intra-operatively, the potential effects of the 
drugs and the procedure should be revisited. We also observed a significant improvement in 
perfusion based on our DOS measurements for patients that received an intervention. The next 
question we wanted to answer is whether or not that improvement is larger in treated 
angiosomes. This angiosome analysis is discussed in the next section. 
 









(µ ± σ) 
p-value 
(without S32) 
Normalized Pooling Rate (AU) 0.03 ± 0.11 0.19 ± 0.24 0.0002* 
Normalized AUC (AU) 0.8 ± 4.7 7.9 ± 9.6 0.0002* 
Normalized Rise Time (s) -0.77 ± 8.13 -7.4 ± 10.7 0.0013* 
Percent Change (%) 5.6 ± 14.9 2.3 ± 25.8 0.53 
 
2.2.4 Post-Operative Angiosome Analysis 
The angiosome concept states that the blood supply for a volume of tissue is fed from a specific 
source artery. This concept applies for the patients receiving interventions. According to this 
theory, an intervention in the posterior tibial artery (PTA) would improve perfusion in two 
angiosomes in our imaging scheme: the lateral plantar artery (LPA) angiosome, and the medial 
plantar artery (MPA) angiosome. An intervention in the anterior tibial artery (ATA) would 
improve perfusion in the ATA angiosome. An intervention in the peroneal (PERA) would 





upstream of these tibial arteries, such as the superior femoral artery (SFA) and the popliteal 
artery (POPA). The following analysis looks at whether the DOS measurements show patterns of 
increased perfusion according to the angiosome theory.  
2.2.4.1 Tibial Revascularizations 
Tibial revascularizations refer to interventions on the tibial vessels (ATA, PTA, and PERA). To 
characterize how well DOS measurements capture the angiosome theory in this study, we first 
looked at patients that only received tibial revascularizations. In these cases, the angiosome 
concept directly applies and factors such as other diseased vessels are minimized.  
 There are 8 patients that received only tibial revascularizations. These patients are broken 
down in Table 2-2. For this analysis, we also look at the change in the DOS measures pre- and 
post-operatively. Instead of grouping all of the channels measuring different angiosomes 
together, we separate the DOS measurements by channels. For patients receiving ATA 
interventions, we expect to see larger changes in the ATA channel that measures the perfusion in 
that angiosome in comparison to the other channels. For the patient receiving a PTA 
intervention, we expect to see larger changes in the PTA channel. The PTA also feeds the LPA 
and MPA angiosome. S17 received an intervention in the PERA but did not have a channel 
measuring this angiosome.  
Table 2-7: Table of patients with receiving only tibial revascularizations broken down by 
ATA, PERA, and PTA arteries. *S17 did not have a channel measuring the PERA 
angiosome. 
ATA  PERA  PTA 







Figure 2-25: Plot of the post-op changes in normalized pooling rate for each channel on 
patient S44, who had an angioplasty in the peroneal artery. There is a much larger change 
in perfusion in the peroneal channel. 
 
Patient S44 did have a channel measuring the PERA angiosome perfusion. Patient S44 was 
described earlier in section 2.2.2.1. This was an angioplasty for the restenosis of the distal 
anastomosis of a previous femoral-peroneal bypass graft. The distal anastomosis was proximal to 
the patch placement. A plot of the post-operative changes in normalized pooling rate (NPR), 
broken down by angiosome channel, is shown in Figure 2-25. We expect that the NPR for the 
PERA angiosome will be higher than the other angiosomes. Indeed, the PERA angiosome, 
highlighted in the dotted rectangle, is greater than the ATA and LPA angiosomes.  
For the four patients with revascularizations in the ATA, a plot of the post-operative 
changes in the NPR is shown Figure 2-26. Each line represents one patient with the points 
representing the NPR measure for the respective angiosome. Here, we expect that the NPR of the 







Figure 2-26: Plot of the post-operative changes in normalized pooling rate for patients 
only receiving treatment in the anterior tibial artery. There is no significant difference 
(p=0.595) in the change in perfusion between channels.  
 
However, we see that this is not the case. A repeated measures ANOVA resulted in a non-
significant difference (p=0.594) between the angiosome channels. In fact, none of the patients 
show a much larger change in the ATA angiosome. This may be due to the nature of the 
intervention and measurement location in these specific patients. In patient S44 above, large 
changes in perfusion were expected as a result of the revascularization. The revascularization 
was an angioplasty of an existing infrapopliteal bypass anastomosis which resulted in a distinct 
in-line improvement in blood flow to the PERA angiosome. The measurement probe for the 
PERA angiosome was placed just distally to the treated anastomosis, and more proximal than the 
other channels. However, in ATA revascularization patients, the interventions were not expected 
to have as large of an effect and the measurement locations were all relatively distant from the 
intervention site. The collateral network of vessels assisted in providing a global improvement to 
the foot at the level of the measurement locations. In addition, the distal disease was diffuse and 





correlation between the treated vasculature and angiosome perfusion in the DOS measures.  To 
do this, we looked at methods to incorporate all the patients in the analysis.   
 
2.2.4.2 Revascularized Angiosomes versus Collateral Angiosomes  
Here, we looked at incorporating all patients receiving an intervention. The idea is that an 
intervention in a proximal artery such as the SFA or the POPA would result in improvements in 
all of the foot angiosomes if none of the tibial vessels were occluded. However, if the PTA was 
occluded, then the ATA and PERA angiosomes might have larger improvements in perfusion. In 
this case, the ATA and PERA angiosomes are grouped together and referred to as ‘revascularized 
angiosomes’. The other angiosomes being fed by the occluded PTA, including the PTA and 
LPA, are grouped together and referred to as ‘collateral angiosomes’. These angiosomes may 
have improvements even though the artery directly feeding it is occluded. This occurs due to 
collateral circulation between angiosomes via minor vessels. The toe clip channel, named the 
‘MPA’, is actually fed by both the MPA and the ATA. In this case this channel would be grouped 
with the revascularized angiosomes. For each patient, the channels are categorized as measuring 
revascularized angiosomes or collateral angiosomes based on the intervention location(s) and the 
occlusion status of the tibial vessels. The occlusion of the tibial vessels is determined from a 






 Figure 2-27: Plot of the differences between normalized pooling rate DOS measurements 
for revascularized angiosomes and collateral angiosomes. There is no significant 
difference between them (p=0.83). 
 
Grouping the angiosomes in this way results in two groups: revascularized angiosomes and 
collateral angiosomes. We expect the revascularized angiosomes will have larger post-operative 
changes than the collateral angiosome counterparts. In order to compare the two groups, the 
measures for the revascularized and collateral angiosomes are averaged for each patient. This 
gives us one pair of measures per patient. Some patients had occlusions in all tibial arteries. In 
this case, all of the angiosomes are grouped with the collaterals. This excluded the patient from 
this analysis, since was no revascularized angiosome existed to compare to. After excluding all 
such patients, 16 patients were left for analysis. A paired t-test between these groups reveals a 
non-significant difference (p=0.83, Figure 2-27). A table of the statistics for other features is 













(µ ± σ) 
Collateral 
Angiosome 
 (µ ± σ) 
p-value 
Normalized Pooling Rate (AU) 0.29 ± 0.12 0.29 ± 0.13 0.83 
Normalized AUC (AU) 10.8 ± 4.4 11.5 ± 5.0 0.5 
Normalized Rise Time (s) -10.36 ± 5.8 -13.7 ± 9.3 0.06 
Percent Change (%) 5.6 ± 14.9 2.3 ± 25.8 0.53 
 
Immediately post-revascularization, both directly and indirectly revascularized 
angiosomes show an improvement. Directly revascularized angiosomes do not have a larger 
improvement in comparison to collateral or indirectly revascularized angiosomes. This can be 
explained by the presence of arterial-arterial connections and the collateral vessel systems that 
connect the angiosomes.  
2.2.5 Longitudinal Analysis Based on Clinical Assessment 
One of the major goals of monitoring revascularizations is to be able to determine if a second 
revascularization will be necessary. With DOS, we hope to recognize this by directly measuring 
the perfusion in the foot. Methods of grouping the patients into outcome groups include whether 
the arterial duplex exam showed any significant changes in flow, whether the patient underwent 
a second revascularization for the same leg, or grouping based on an overall clinical assessment. 
Grouping solely based on the arterial duplex results in this study is difficult due to the operator 
dependency of the results. The duplex results themselves may also reveal a new occlusion, but 
which may not be clinically relevant. The next method of grouping is according to whether or 
not the patient underwent a second revascularization. However, this may not be the best outcome 





patient needs an intervention, but is not a good candidate for revascularization. This could be due 
to the risk-benefit ratio or the patient’s overall condition. Some patients do not undergo another 
interventional angiogram because the effects may not last. Some patients do not get a bypass 
because a suitable conduit is not available. In this analysis, we group the patients based on 
overall clinical assessment. This assessment takes into account the non-invasive flow studies 
(NIFS), arterial duplex exam findings, and patient symptoms. Based on the clinical assessment, 
patients in the study are classified as ‘recovered/stable’ or ‘relapsed’. Most patients relapsed 
patients received a second interventional angiogram. In the analysis, we only included patients in 
the recovered / stable group if they were not lost to follow-up at the 6-month time point to reduce 
the bias introduced if the reasons for loss are related to outcome. Although many patients had a 
good clinical assessment at the 1- and 3-month time points, it is not known if that status was 
maintained. 
A summary of the patients used in this analysis is described in Table 2-9 and Table 2-10. The 
patient populations of the groups are consistent with the study population. 
 
Table 2-9: Table of patient classification into recovered / stable and relapsed groups (and 
not lost to follow-up at 6-months) 
Recovered / Stable  Relapsed 










Table 2-10: Patient population characteristics for outcome groups 
 Recovered / Stable Relapsed 
Age 81.0 ± 11.7 years old 73.3 ± 14.6 years old 
Female 67% 25% 
Male 33% 75% 
Chief Complaint: Claudication 67% 50% 
Chief Complaint: Wounds 33% 50% 
Diabetes 83% 75% 
Hypertension 67% 88% 
Hyperlipidemia 50% 50% 
Smokers / Former Smokers 67% 38% 
 
First, we looked at the first three time points where we have the most complete set of data. A plot 
of the pre-operative, post-operative, and first follow-up (within 1-month post-operation) 
normalized pooling rate values are shown in Figure 2-28. A repeated measures ANOVA was 
performed on this data to determine whether there was a significant effect of time and difference 
in groups. There is a significant effect time on the measure, but no significance of the outcome-
time interaction. A summary of the significance repeated measures ANOVA is shown in Table 
2-11. Although there is no significance between the outcome groups, a few interesting 






Figure 2-28: Normalized pooling rate of the relapsed and recovered groups for the pre-, 
post-, and 1-month follow-up. 
 
Table 2-11: Table of repeated-measures ANOVA analysis on the first three time-points 








Normalized Pooling Rate (AU) p < 0.0001 p = 0.105 
Normalized AUC (AU) p < 0.0001 p = 0.086 
Normalized Rise Time (s) p < 0.0001 p = 0.106 
Percent Change (%) p = 0.041 p = 0.120 
 
2.2.5.1 Pre-Op Baseline Characteristics 
To see if there was a difference in these groups prior to the intervention, for example if the 
relapsed group started off with significantly less perfusion than the recovered group, the pre-





of the results is shown in Table 2-12. There was no significant difference between the groups’ 
pre-operative measures. Thus, the outcomes were probably not due to the level of disease in the 
patients.  




(µ ± σ) 
Relapsed 
Pre-Op 
 (µ ± σ) 
p-value 
Normalized Pooling Rate (AU) 0.79 ± 0.15 0.72 ± 0.14 0.12 
Normalized AUC (AU) 27.7 ± 5.7 25.0 ± 5.7 0.09 
Normalized Rise Time (s) 32.9 ± 6.2 31.4 ± 4.7 0.33 
Percent Change (%) 31.8 ± 19.4 30.9 ± 19.5 0.86 
 
2.2.5.2 Post-Op Revascularization Improvements  
To determine if the improvement in perfusion from the intervention was significantly different 
between the groups, we analyzed the change in post-operative measurements relative to the pre-
operative measurements (i.e. the difference). If the recovered group saw significantly more 
improvement post-operatively then the relapsed group, then the post-operative perfusion measure 
may be an indicator of the patient outcome. There was a significant difference in the change in 
post-operative measures for all features (see Table 2-13). However, the relapsed group had larger 
post-operative changes than the recovered/stable group. A plot of the post-operative changes for 






Figure 2-29: Change in post-op normalized pooling rate relative to pre-op for the relapsed 
and recovered groups (p=0.0044) 
 




(µ ± σ) 
Recovered 
Post-Op Change 
 (µ ± σ) 
p-value 
Normalized Pooling Rate (AU) 0.38 ± 0.16 0.25 ± 0.13 0.0044 
Normalized AUC (AU) 14.2 ± 6.7 9.4 ± 4.9 0.0086 
Normalized Rise Time (s) -15.3 ± 8.3 -8.6 ± 4.6 0.0058 







Figure 2-30: Change in 1-month follow-up normalized pooling rate relative to pre-op for 
the relapsed and recovered groups (p=0.46) 





(µ ± σ) 
Recovered 
1-Mo Change 
 (µ ± σ) 
p-value 
Normalized Pooling Rate (AU) 0.08 ± 0.19 0.13 ± 0.21 0.46 
Normalized AUC (AU) 3.0 ± 7.5 5.8 ± 8.4 0.35 
Normalized Rise Time (s) 0.67 ± 7.9 0.68 ± 6.8 0.99 
Percent Change (%) 0.4 ± 30.9 -1.7 ± 30.9 0.86 
 
2.2.5.3 Normalized 1-Month Follow-Up 
In order to better investigate the changes in the DOS measures over time, the measures are 









After this normalization, a follow-up measure at 0 would be at the same level as pre-operation, 
indicating the blood flow relapsed to pre-operative levels. A follow-up measure at 1 would be at 
the same level as immediately post-operation, indicating the patient maintained the improved 
blood flow from the treatment. We expect that the recovered/stable group will have follow-up 
measures closer to 1, while the relapsed group will have follow-up measure closer to 0. A plot of 
the normalized pooling rate measures for the two groups is shown in Figure 2-31. 
Figure 2-31: Normalized 1-month follow-up of the normalized pooling rate for the 
relapsed and recovered groups (p=0.65) 
Table 2-15: DOS feature statistics for normalized features at the 1-month follow-up for 




Normalized Pre-Post-Op Change 
(µ ± σ) p-value 
Relapsed Recovered 
Normalized Pooling Rate (AU) 0.35 ± 0.35 0.59 ± 0.65 0.65 
Normalized AUC (AU) 0.37 ± 0.35 0.62 ± 0.57 0.17 
Normalized Rise Time (s) -0.06 ± 0.76 -0.26 ± 0.89 0.56 






There is no significant difference between the two groups in at the 1-month follow-up when 
considering all angiosomes. However, upon further investigation directly revascularized 
angiosomes maintain the post-operative improvements while indirectly revascularized 
angiosomes seem to have decreased perfusion. This is investigated by segmenting the 
normalized 1-month follow-up by the type of angiosome. Figure 2-32 shows a box plot of the 
results. There was a significant difference in the revascularized angiosomes between the relapsed 
and recovered groups (p=0.05). 
 
Figure 2-32: Normalized change (to pre- and post-op values) in the normalized pooling 
rate broken down by relapsed and recovered groups, and revascularized and collateral 
angiosomes. 
Table 2-16: DOS feature statistics for normalized features at the 1-month follow-up for 




Normalized Pre-Post-Op Change 
(µ ± σ) p-value 
Relapsed Recovered 
Normalized Pooling Rate (AU) 0.38 ± 0.37 0.90 ± 0.58 0.05* 
Normalized AUC (AU) 0.39 ± 0.36 0.89 ± 0.53 0.06 





Percent Change (%) 0.1 ± 1.1 3.2 ± 6.3 0.22 
 
Qualitatively, we also see there is a separation between the two outcome groups after the 6-
month time point (Figure 2-33). This study is ongoing and the data at follow-up time points are 
limited. With more data, we hope that these trends become clearer and statistically significant. 
 
Figure 2-33: Plot of the normalized NPR measures available for each time point. The 
diamond and bars represent the mean and standard deviations. Each point represents a 
data point. 
2.2.6 Comparison to Clinical Measures  
In addition to utilizing our DOS measures to monitor the effect of the intervention and the 
disease progression post-intervention, we characterized how well the DOS measures correlated 
with the current clinical measures available.   
2.2.6.1 Comparison to ABI Measurements 
Despite removing overtly elevated ABI measurements (i.e. ABI >1.3), there was no strong 





channel. However, ABI measurements are falsely elevated in calcified arteries while still being 
less than 1.3. Thus, these ABI measurements do not accurately represent the level of disease.  
 
 
Figure 2-34: Linear regression of ABI measurements at the dorsal pedis compared to 
NPR perfusion measurements for each DOS channel 
 
2.2.6.2 Comparison to PVR Measurements 
PVR measurements are generally collected at the dorsal pedis (DP) level, or ankle level, and at 
the metatarsal level of the foot in the patients in this study. As described earlier, the PVR 
waveforms are classified as Normal, Mild, Moderate, or Severe. Thus, we expect the PVR 
waveforms to correlate with the ATA patch, the LPA patch, and the toe clip. The PTA and 
PERA patches are placed such that they may not capture the perfusion at the same level as the 
PVR measures. The NPR measurements (Figure 2-35) should decrease with PVR severity. The 
calf/peroneal patch shows a general decrease, however it is the rise time measure that shows the 
best correlation with the PVR measures. The rise time should increase with increasing PVR 






Figure 2-35: PVR measurements at the metatarsal level compared to normalized pooling 
rate measurements for each DOS channel. Black line and whiskers represent the mean 
and standard deviations. 
 
 
Figure 2-36: PVR measurements at the metatarsal level compared to normalized rise time 







2.3.1 Post-revascularization Changes and Outcome Prediction 
Angiosome-directed revascularization of underperfused angiosomes is a promising 
method for increasing the effectiveness of revascularization for PAD patients. A number of 
recent studies support angiosome-directed revascularization for ischemic wound healing versus 
indirect revascularization, which increases perfusion specifically for areas of ischemic foot 
wounds to enhance tissue healing. The ability to better assess the perfusion in the foot is 
important in optimizing and evaluating revascularization. However, current methods of 
evaluation do not measure the perfusion in the foot and diffuse optical imaging methods are be 
better suited.  
 In this study, we demonstrated DOS perfusion measurements may be useful in 
monitoring revascularization procedures. There was no significant difference when no 
revascularization was performed in diagnostic angiography cases. After revascularization, we did 
observe significantly faster accumulation of blood across all angiosomes during the venous 
occlusion, which is associated with better perfusion.  
According to the angiosome theory, there may be a larger improvement in directly 
revascularized angiosomes. However, when grouping angiosomes according to directly 
revascularized and indirectly or collateral angiosomes, we found no significant difference 
between the two types of angiosomes. This observation is similar to a recently published study 
measuring microperfusion in each angiosome intraoperatively and post-operatively using 





patent arterial-arterial connections and the collateral development from choke vessels in the 
chronically ischemic foot. 
There are numerous arterial-arterial connections between the angiosomes in the lower 
limb. Direct arterial-arterial connections connect the PERA, PTA, and ATA angiosomes at or 
above the ankle (PERA and PTA angiosomes via three perforators above the ankle, at the ankle, 
and just above the Achilles; PERA and ATA at the lateral malleolar level; PTA and ATA at the 
medial malleolar level). The MPA and LPA are both branches from the PTA, but are also 
connected distally at the cruciate anastomosis. The MPA and ATA angiosomes are connected via 
proximal, medial, and distal perforators. The LPA and ATA angiosomes are also connected via 
numerous distal and proximal perforators. The main connection between angiosomes is the pedal 
arch, which is a direct connection between the LPA and DPA. In addition, a well-developed 
collateral network also links the angiosomes allowing global perfusion in the foot regardless of 
the revascularized artery.  
Reconstituting the blood supply remains crucial whether it be from major angiosome 
source arteries or from existing collaterals and arterial-arterial connections such as the pedal 
arch. Despite the occlusion of one or more main arteries to the foot, numerous indirect arterial-
arterial connections can allow alternative routes of blood flow if the direct route is disrupted or 
compromised. In 9-12% of patients, there are anatomical variations in the vasculature that can 
affect the anatomic division of angiosomes in the foot [176-178]. For example, the DPA is 
absent or extremely attenuated in 12% of people [179] and the pedal arch is absent or incomplete 
in up to 80% of limbs [180, 181]. In addition, the patency of arterial-arterial connections is 





pedal arch has been noted as an important factor in the success of revascularization procedures 
[8, 182-184].  
 While all angiosomes show a significant post-revascularization improvement, with no 
significant difference between directly revascularized and indirect or collateral angiosomes, there 
was a difference between the angiosomes at the first follow-up.  Our preliminary results indicate 
that the maintenance of perfusion in revascularized angiosomes in the weeks following 
revascularization correlates with clinical improvement.  
These results underscore the importance of non-invasive monitoring of perfusion in 
revascularization procedures. In the DOS measures of perfusion, there are signs of relapsing 
effects in revascularized angiosomes associated with clinical decline. The mechanisms 
underlying these findings remains incompletely understood. The physiological mechanism for 
this observation may be explained by the temporal dynamics of the vascular remodeling in 
response to revascularization and the notable difference between results for surgical and 
endovascular revascularization according to the angiosome model of reperfusion.  
In endovascular revascularization procedures, the quality of the existing collateral 
network in the foot may play in important role in the success of the intervention. Faster wound 
healing and AFS have been associated with patients with complete or partially complete pedal 
arches versus absent pedal arches [77, 118, 182, 185]. However, the quality of the collateral 
network seems to play less of a role in bypass cases where the flow to the ischemic angiosome is 
delivered via the complex network of collateral vessel. This indirect revascularization via bypass 
procedures is considered sufficient and achieves similar results compared to the DR approach. 





inconsistency may be explained by exploring revascularization physiology between surgical and 
endovascular procedures. 
The angiosome theory was derived from healthy cadavers, but arterial occlusions and 
subsequent revascularization induces time- and pathology-dependent tissue changes towards 
recovery. Under healthy conditions, the response to gradually progressive limb ischemia from 
arterial occlusions involves the promotion of angiogenesis and arteriogenesis in an attempt to 
increase the blood supply to the affected limb. Angiogenesis is the sprouting of new capillaries 
from existing blood vessels resulting in an increased density of capillaries, driven by local tissue 
ischemia [187]. While angiogenesis and arteriogenesis can take place simultaneously, 
angiogenesis is of little value for the functional replacement of occluded arteries. Accordingly, 
arteriogenesis appears to be an important part of the pathophysiology of PAD continuing for a 
long time after onset of disease. 
Most notably, collateral arteries develop to bypass occluded arteries and interconnect 
different angiosomes via arteriogenesis. The flow in these choke vessels is normally very low. 
However, as the arterial stenosis progresses, the pressure gradient along the artery increases 
eventually increasing the blood flow through the choke vessels. The increased blood flow 
increases shear stress and promotes arteriogenesis [188-190]. Mechanotransduction of the shear 
stress in endothelial cells triggers multiple cascades intracellular signaling pathways to modulate 
gene expression, ultimately stimulating growth and proliferation. The leads to a marked increase 
in vessel diameter (up to fivefold) and length (corkscrew tortuosity) [189]. 
However, this process is self-limiting since fluid shear stress falls with the increase in 
collateral vessel diameter [191-194]. The shear stress normalizes early in the process so that 





[191, 195]. An efficient collateral circulation contains a few larger vessels with low resistance 
over many small vessels with high resistance. A few large vessels that are able to maintain the 
shear stress mature and most of the other small vessels regress [196]. Once the larger vessels 
mature, they do not disappear. Although this process is important since the development of the 
large collaterals is the key to the restoration of blood flow, it is not yet well-understood and may 
differ for different tissue regions. 
Revascularization procedures result in hemodynamic changes that induce vascular 
remodeling in the collateral foot vessels. The sudden increase in blood flow to the foot may 
prompt large long-lasting changes. The degree of remodeling may depend on the degree of the 
restoration of blood flow, which is exemplified in surgical versus endovascular 
revascularizations [185]. Bypass procedures drives more blood flow to the foot in comparison to 
endovascular interventions. In endovascular procedures, the treated vessels are often diffusely 
diseased and are smaller in diameter than the conduits used in bypass. The larger blood flow 
generated from bypass increases the overall shear stress in distal vessels. The increased shear 
stress promotes larger changes in the collateral network. The further development of the 
collateral network aids in the perfusion in the foot. This may explain why indirect 
revascularization produces similar results as direct revascularization in bypass cases. The larger 
blood flow driven by bypass may induce enough collateral development to bypass distal 
occlusions and connect angiosomes within the foot.  
In addition to the degree of blood flow restoration, the hemodynamic remodeling process 
after revascularization is dependent on other factors, including inherent choke vessel anatomy, 
existing development of the collateral network, and the ability to remodel. There is a wide 





develop into collaterals [197]. By the time of the revascularization, some patients may have 
already fully developed and maximized the collateral network. Thus, further support from 
development of collaterals in response to the revascularization procedures is not possible.  
Methods to maintain high blood flow through the choke vessels may increase the growth 
and development of long-lasting functional collaterals  [189]. By maintaining an increased shear 
force, the vessels are kept in the active enlargement phase. Physical exercise increases blood 
flow and has been linked to increased collateral vessel enlargement and angiogenesis. However, 
the arteriogenic effects of exercise account for less than 30% of functional improvement in 
walking distance, with the majority of the improvement being attributed to less reliance on 
anaerobic metabolism and efficient energy use [189, 198, 199]. However, the importance of 
collaterals on walking and functional improvements may be underestimated [200]. This suggests 
that further improvements may be seen in patients who are able to exercise and find functional 
improvement from the revascularization procedures. The ability of patients to exercise and 
promote arteriogenesis may play a role in increasing the blood flow in the foot.  
However, the vascular remodeling processes are impaired by commonly prescribed 
cardiovascular drugs [201, 202]. Collateral remodeling is further impaired in smokers, the 
elderly, and patients with diabetes, dyslipidemia, and hypertension [203-209]. The decreased 
ability of choke vessels to dilate and permit collateral flow affects the quality of the collateral 
network in these patients. It is likely that there is reduced collateral development in response to 
revascularization, and thus revascularization may be more likely to fail to improve the patient 
outcome. This reasoning is in line with evidence that the quality of the existing collateral 
network before revascularization is more important for revascularization success in diabetes 





is hampered. In patients without diabetes, this revascularization may promote further collateral 
development. In addition to a high prevalence of distal medium-sized foot vessels (e.g. dorsal 
pedis, plantar arch, or distal peroneal branch) occlusions, achieving direct in-line reperfusion is 
more difficult in calcified tibial arteries. Understanding and monitoring the remodeling process 
even more relevant in this population.  
DOS provides valuable insight into revascularization related hemodynamic remodeling in 
PAD patients. As more patients are recruited, we may be able to better correlate the 
revascularization response to the collateral network structure by taking into account the various 
factors affecting revascularization associated remodeling. Still, we were able to discover early 
trends that discriminate revascularization successes from failures. Quick identification of 
revascularization failure enables planning for alternative therapies.  
 
2.3.2 Study Limitations 
While we discovered some promising trends in our preliminary analysis, the results are limited 
by the small number of patients which is partially attributed to a high attrition rate. This study is 
also limited in its heterogeneity of the patient and procedure characteristics, including the 
patient’s stage of PAD (e.g. IC vs. CLI or Rutherford classification), wound characteristics and 
adjunct treatment protocols, risk factors (e.g. DM and duration, ESRD, smoker), and type of 
revascularization (e.g. primary vs secondary, location, and angioplasty vs stenting). In addition, 
this analysis does not include common outcome measures or endpoints. Incorporating Dopper 





While current literature focuses on DR versus IR in below-the-knee revascularizations for 
wound healing, this work uses DOS perfusion measurements to investigate angiosome concepts 
in both IC and CLI patients undergoing infrainguinal and BTK revascularizations. Broader 
inclusion criteria may be more likely to be representative of the diverse patient populations seen 
in practice. Additionally, their studies reflect real-world treatment decisions and management 
protocols produce results with greater generalizability. As the study continues, we hope to see 
more power in the statistical significance of the observed trends in the preliminary analysis. As 
more patients are enrolled, it may be possible to stratify patients into IC and CLI grounds. Future 
analysis with more patients can also aim to adjust for baseline disparities using propensity 
scoring and to characterize the effect of edema, HTN, peripheral neuropathy, quantification of 
runoff quality, etc. on the measurements as covariates or with more complicated models. 
Collection of standard endpoints may also be useful in future analysis to enable comparison to 
other studies. 
DOS is a promising tool, but further investigation is needed to fully explore these 
findings and determine its best place in within the management of PAD. We hope to gain the 
necessary insight to begin larger, more controlled studies in the future. 
 
2.3.3 DOS Measurement Limitations 
The DOS measurements in this study are sufficient to elucidate valuable information, however it 
has limitations. In the reflectance geometry, the most likely path of photons between the source 
and detector is described by a banana-shaped curve. The reconstructed values represent the 





detector. The depth of the banana-shape is generally about half the distance between the source 
and detector [211]. Thus, our DOS patch measurements represent a localized area of tissue and 
are highly position dependent. The contact with the tissue (e.g. the pressure applied by Velcro 
strapping) also affects the measurements. It is difficult to place the DOS patches at the same 
location with the same pressure at different monitoring time-points, resulting in a higher 
variability in the DOS measurements. 
Tomographic approaches are less dependent on the location because they utilize more 
sources and detectors to encompass the tissue and generate spatial maps of chromophore 
concentrations. Additionally, non-contact approaches can reduce the contact-based measurement 
effects. The non-contact form factor is also useful in avoiding open wounds. This forms the basis 





3 Development of a Contact-free DOT System 
3.1 Background 
Many traditional diffuse optical tomographic (DOT) imaging systems employ optical fibers in 
direct contact with the tissue surface to deliver and collect light. Optical fibers can be placed 
anywhere around the object, enabling flexibility for capturing reflection and transmission 
measurements without additional optics. Fiber-based systems also generally have a higher 
dynamic range and frame since each fiber collects light independently and in parallel [212-215].  
However, the use of optical fibers has several limitations. The number of the fibers that 
can be used is limited by the bulkiness of the fibers themselves. These fibers can also be 
cumbersome and time-consuming to place. Establishing proper contact between the fiber and 
tissue is difficult. Coupling issues between the fiber and tissue compounds these problems. The 
bulk of fibers around the imaged object also make it difficult to recover complex object 
geometries and the fiber positions. Furthermore, contact-based systems are especially limited in 
patients with open wounds, which is common in PAD patients that present with foot ulcers.  
Recently, fiber-less contact-free systems have emerged to overcome these limitations and 
the growing interest in the use of DOT for clinical applications has fueled further development of 
these systems. In fiber-less systems, wide field detectors such as charged coupled devices (CCD) 
or complementary metal–oxide–semiconductor (CMOS) sensors are utilized which allow for a 
higher spatial resolution of detection points and avoids placement issues of fibers [216-219]. 
Scientific CCD cameras perform better in low light environments due to lower noise and higher 





Placement of optics to guide light to the wide field detector enables the contact-free detection of 
light. Although camera sensors have lower dynamic range and slower frame rates than fiber-
based counterparts, camera detection have a much higher resolution and the geometry of the 
imaged object can be more easily extracted.  
Continuous-wave (CW) DOT systems deliver constant intensity light to the object and 
measures the attenuation of the light intensity after passing through the object. The CW mode 
allows for simple low-cost instrumentation while attaining fast frame-rates and high signal-to-
noise-ratio (SNR). Although it is difficult to accurately differentiate between absorption and 
scattering in tissue in using CW techniques [220], the majority of changes during a venous cuff 
occlusion is due to absorption of Hb and HbO2 while scattering remains relatively constant. This 
makes CW systems ideal for imaging hemodynamics.  
Many current non-contact CW systems have been designed for pre-clinical use [221] and 
translating such systems to the clinical is non-trivial. Systems geared for clinical use largely 
employ a single view mode. These systems use reflectance only to measure oxygen saturation in 
the skin and muscle.  Transmission only non-contact systems have been developed for hand and 
finger imaging [222]. Additionally, clinically geared systems image at primarily shallow depths 
(<1cm).  
The first fiber-less, non-contact imaging system considered by our group was based on a 
transmission-only configuration [223]. The basic design of this CW DOT system is shown in 
Figure 3-1. Two laser diodes, operating at wavelengths l = 660nm and l = 860nm, are de-
multiplexed to 20 multimode source fibers via a 2x20 microelectromechenical (MEMS) optical 
switch. The switch time-series multiplexes the wavelengths and then the source fibers. Light 





without contact to the skin. Transmitted light through the foot is reflected off a mirror angled at 
45º to an electron multiplying charge coupled device (EMCCD) camera. LabView software 
synchronizes the switch and camera data collection. This system is capable of imaging foot 
dynamics at up to 1Hz.  To obtain the geometry of the foot for reconstruction, multiple 
photographs of the foot and source positions are captured. The photographs are merged to create 
surface mesh using PhotoModeler Scanner software.  
 
Figure 3-1. Single-view non-contact DDOT system in a transmission only configuration 
 
To improve on this system, I have developed a multi-view non-contact dynamic diffuse optical 
tomography system for imaging the blood flow in the foot using a mirror-based scheme. A non-
contact system will be easier to use in the clinical setting and will overcome challenges with 
traditional evaluation methods by providing a direct spatial measure of perfusion in the foot 







3.2 Multiple-View Contact-free DOT System For PAD  
3.2.1 System Design Requirements and Considerations 
The overall approach taken to develop a multiple-view contact-free DOT system was to design 
and optimize a CW system configuration that incorporates both reflection and transmission 
information with a mirror-based scheme. The CW DOT system was designed with the following 
features and requirements in mind: 
• Low cost system (<80k) 
• Compact overall size (small footprint – 2x2ft, and reasonable height, 3ft) for easy 
integration in the clinical setting.  
• Simultaneous non-contact reflection and transmission measurement with a single camera. 
While a dual camera setup is possible, the new design uses an EMCCD camera for low-
light imaging and to keep the cost of the system low.  
• Patient interface to image the hemodynamics of the mid-metatarsal area of the foot such 
that the patient is seated with the foot angled at 18º off the floor.  
o Ischemic ulcers are typically located at the termination of arterial branches at the 
forefoot and at sites of increased focal pressure.  The mid-metatarsal level of the 
foot can be used to differentiate between healthy and PAD patients [163, 164].  
o We have previously found this posture is comfortable and provides the best and 
most consistent physiological signal for imaging vascular dynamics [224].  
• Integrated surface geometry acquisition. Previous systems either scanned the foot 
geometry outside of the system, which required additional co-registration and was prone 





3.2.2 System Overview 
A photograph of the implemented system is shown in Figure 3-2 and the overall schematic of the 
system is shown in Figure 3-3. The seated patient places his or her foot inside the imager on an 
angled platform with an open rectangular transmission window. The foot is held in place 
laterally from both sides by padded blocks. These padded blocks slide in from each the side of 
the foot and lock into place. In this way, the foot is able to rest on the platform to remain stable 
and limit motion artifacts during imaging. The foot is illuminated from above. Reflected light is 
attenuated by a filter and captured by a camera above the foot. Transmitted light is reflected by a 
system of mirrors to the same camera. This setup also allows a 3D surface scanner above the foot 
to obtain the dorsal foot geometry.  
 







With this overall design, the DOT system can be broken down into five units: (1) input unit, (2) 
imaging head, (3) detection unit, (4) control unit, and the (5) surface scanner. The input unit 
delivers CW source point illuminations to the top of the foot. The imaging head projects light 
emitted from the foot to the detection unit. The detection unit captures the emitted light from the 
top and bottom of the foot. The control unit manages the imaging sequences.  The surface 
scanner obtains the dorsal foot geometry. The following sections describe each unit in detail. 
 
































3.2.3 Input Unit 
The main components of the input unit are two 350mW laser diodes with built-in thermoelectric 
control (660nm and 860nm, Intense Inc., USA). These diodes are driven by two laser drivers 
(ITC102, Thorlabs Inc., USA) in constant-current mode to provide constant CW light. The two 
wavelengths are time-series multiplexed onto a single graded-index multimode fiber patch cable 
(62.5µm core, 1m length, FC/APC connectors) using an optical MEMS switch (Leoni, 
Germany).  
The light from the patch cable is collimated (F240APC-780, Thorlabs Inc., USA) to 
approximately a 2mm spot size, measured using the 660nm. The collimated light is coupled with 
a 2D galvanometer scanner (12.5º x 12.5º scanning angle, GVSM002-Silver, Thorlabs Inc., 
USA) placed approximately 25cm above the platform. The galvanometer deflects the collimated 
light to the top of the foot to provide multiple source point illuminations with a resolution of 
0.0008º and a step response of 300µs.  
The laser intensity at the foot is tuned to deliver approximately 30mW for 860nm and 
40mW for 660nm. For these wavelengths, integration times, and spot size, this power is still 
within safe limits [225]. 
3.2.4 Imaging Head 
The imaging head is responsible for channeling re-emitted light from the foot to the detection 
unit and is comprised of the patient interface and a system of mirrors to direct the diffusely 
transmitted light to the detection unit. Ray trace simulations were performed on various designs 





3.2.4.1 Ray Trace Simulations and Optimization 
The imaging head simultaneously captures back-reflected light from the top of the foot and 
transmitted light from the bottom of the foot. The back-reflected light is directly captured by the 
camera sensor, while transmitted light from the bottom of the foot is captured through a system 
of mirrors (see Figure 3-3). The amount of transmitted light through the foot is low in 
comparison to reflected light. It is limited by the power of the source illumination, the properties 
of the foot itself, and the placement of the foot, mirrors, and camera relative to each other.  
Ray trace simulations for various schemes and component positions were modeled 
(TracePro, Lambda Research Corporation, Littleton, MA) to optimize the light collection 
efficiency of transmitted light from the bottom of the foot to the detection unit described below. 
Both single and double mirror schemes were evaluated. In a single mirror scheme, the mirror 
captures and reflects the light from the bottom of the foot onto the camera. In a double mirror 
scheme, the first mirror reflects the light from the foot onto a second mirror, which projects the 
light to the camera. In both cases, a region in the bottom half of the camera captures the light 
from the mirror scheme. We assumed an 8.2x8.2mm image sensor area coupled with a 14mm 
f\2.8 lens system for a 32.6º angle of view camera-lens system, where the lens was modeled as a 
simple thin lens. The component positions and schemes we assessed are summarized in Figure 
3-4(a). We modeled various camera-lens and divider positions (shown in grey in Figure 3-4(a)) 
that included in the field of view the mid-metatarsal portion of the top of the foot while keeping 
the system at a reasonable size in height for clinical use, but focused on one configuration which 
optimized the usage of the CCD pixels (shown in black in Figure 3-4(a)) after initial simulations. 
Figure 3-4(b) shows the parameters considered. We assumed a transmission window size of 2in (





platform was also kept at an 18º angle ( ) to have the patient positioned in the optimal setup 
[224]. The variables  and  were varied between 2 and 12 inches while the angles 	and	  
were varied from 15º to 75º independently. We utilized back projections in the simulations and 
counted the number of photons reaching the foot to reduce computation time. Additionally, the 
average optical path length difference between the reflected light and the transmitted light was 
calculated to account for the limited focal depth of the camera.  
 
Figure 3-4. Ray Trace Simulation Designs and Parameters. (a) Designs considered for the 
imaging unit to simultaneously collect reflected and transmitted light. (b) Parameters 
varied in in the simulations. (c) Raw camera image of the foot. 
 
Table 3-1. Optimized Parameters for Imaging Unit Components (shown in Figure 3-4)  
        	  
 4.5 in. 2 in. 4 in. 7 in. 68º 27º 18º 81.9º  
 
Varying the design parameters lead to trade-offs between the transmitted signal and the optical 
path length difference. The final parameter values are described in Table 3-1. Optimized 
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Parameters for Imaging Unit Components (shown in Figure 3-4). The best overall combination 
for maximizing SNR (~16dB) and limiting optical path length difference (~8 inches) uses two 
mirrors to reflect the transmitted light in the single camera system. In the system implementation, 
two mirrors (reflectivity >95% @660nm and 860nm, Nu-Tek Precision Optical Corp., USA) 
were placed at the location of the utilized portion of the modeled mirrors. The resulting raw 
camera image simultaneously shows the top and bottom of the foot in Figure 3-4(c). 
3.2.4.2 Patient Interface 
The patient places his or her foot on an angled platform over the rectangular transmission 
window, but the foot does not cover the entire transmission window. Thus, stray light reflections 
from above the foot can leak into the transmission signal. To prevent this, sliding acrylic pieces 
with highly conformable foam ends can be slid and fixed along guide rails from the sides of the 
enclosure (described in Section 3.2.8). Highly conformable foam is very porous and on its own 
transmits a significant amount of light. To reduce the transmission of light through the foam, the 
foam is covered in a highly flexible silicone material to maintain the foam’s compressibility 
while still keeping stray light from leaking around the sides of the foot. Figure 3-5 shows an 
image of the interface.  
The user can move the acrylic pieces via rods that are fed through shaft collars attached 
to the external enclosure. The shaft collars have a set screw so the acrylic pieces can be locked in 







Figure 3-5. Patient interface to reduce light leakage in the transmission signal. 
 
 







3.2.5 Detection Unit 
A back-illuminated electron multiplying charge coupled device (EMCCD) camera (ProEM 
512B-EX, Princeton Instruments, USA) captures the diffusely reflected and transmitted light 
from the foot.  The transmission signal through the foot can be very low, thus an EMCCD 
scientific camera can ensure collection of the low light signal through the foot. EMCCD’s 
contains an extended serial multiplication register where electrons are accelerated by applying 
high CCD clock voltages. Extra electrons are generated in the silicon by impact ionization during 
the process. The degree of electron multiplication gain is exponentially proportional to the clock 
voltage applied. The EMCCD also has eXcelon™ technology, which provides improved 
sensitivity over a broader wavelength, up to 10x lower etaloning (unwanted fringes in NIR 
region compared to standard back-illuminated CCDs), and lower dark current. 
The camera sensor has an 8.2x8.2mm imaging area (16µm x 16µm pixel size, 512x512 
pixel resolution) that coupled with a lens (14mm f/2.8, Canon, USA) results in a 32.6º angle of 
view. A flat surface area of 16.5x6.4 cm is represented by 420x165 pixels in the reflection 
portion of the imaging area, while a flat surface of 15.24x5.08cm is represented by 232x71 pixels 
in the transmission portion of the imaging area. Thus, the EMCCD acts as a fiber-free wide field 
detector with an approximate spatial resolution of approximately 2.5px/mm in the reflection 
geometry and 1.5px/mm in the transmission geometry.  
The camera has a dynamic range of 16bits (96dB). The EMCCD is thermoelectrically and 
air cooled to -70ºC for low light sensitivity. The CCD camera is sensitive to the NIR range, 
approximately 95%QE at 650nm. However, since the amount of diffusely reflected light is much 
higher than the transmitted light, photons emitted from the top of the foot pass through a fixed 





reflected light does not saturate the CCD. The neutral density filters have an optical density of 
1.8 for the 860nm wavelength and 1.95 for the 660nm wavelength. Strips of high absorbing 
blackout tape (<1e-5% transmittance @ 850nm, T205-2.0, Thorlabs Inc., USA) are secured in 
front of the portion of the lens capturing the reflected light. These strips are placed such that they 
block strips of view of the top of the foot. The source positions can then be positioned on the top 
of the foot such that they align with the camera’s blocked view of the foot. Thus, any specular 
reflections are blocked from being detected by the camera sensor by the blackout tape. This 
allows for better use of the dynamic range of the camera. 
 The camera is operated in full frame mode where the pixels are exposed and read out 
sequentially, which allows for cleaning the CCD where excess charge on the array is 
continuously removed between exposures. This ensures the least amount of noise. Frame transfer 
mode would allow simultaneous exposure-readout operations and could improve frame-rates, but 
the shutter is always open (i.e. CCD is light sensitive whenever the image is not shifting) and 
image smearing can occur when the exposure time is small compared to the frame transfer time. 
Smearing in frame transfer mode could be mitigated by using a gated light source and the expose 
programmed logic out signal.  
The readout time is calculated based on the ROI, binning, and vertical shift rate settings. 
Enabling binning can increase sensitivity and decrease the readout times, however in this study 
we do not enable binning to maintain spatial resolution of the detectors.  
The camera operates in ‘Fast Mode’ for real-time collection of data, where the host 
computer indicates the start of the experiment, and the collection of the all of the frames is run 
according to the timing of the experiment without interruptions from the computer regardless of 





the computer hardware. The camera sends data to the host computer through a Cat5e/6 Gigabit 
Cable to a Gigabit Ethernet (GigE) card.  
Controller gain, or analog gain, is used to change the relationship between the number of 
electrons acquired on the CCD and the analog-to-digital units, or counts, generated. The camera 
is operated at a controller gain of 3 and 5MHz rate for higher precision. This combination leads 
to a conversion gain of 2.63.  
When signal levels in some part of the image are very high, charge generated in one pixel 
may exceed the well capacity of the pixel (i.e. 260ke- in the sensor wells, 900ke- in the 
multiplication gain register), spilling over into adjacent pixels in a process called blooming. In 
this case, a shorter exposure is advisable, with signal averaging to enhance SNR accomplished 
through software. For signal levels low enough to be readout-noise limited, longer exposure 
times, and therefore longer signal accumulation in the CCD, will improve the SNR 
approximately linearly with exposure time until on-chip saturation or loss of dynamic range due 
to the buildup of dark charge in the pixels. The exposure time is set to balance the detection to 
prevent blooming.   
3.2.6 System Control, Synchronization, and User Interface 
3.2.6.1 EMCCD Camera 
In external sync timing, each frame requires a trigger. To trigger an exposure, a 0-3.3V 
logic level TTL-signal pulse is sent to the camera. The rising or falling edge of the trigger 
initiates an exposure. The camera’s logic out TTL signal (0-3.3V) is used to monitor the camera 
status and synchronize external devices. The logic out signal is high when the camera is ready to 





when a trigger is detected and exposure begins. The level does not return to high until after 
readout has completed. The camera checks for a trigger before starting a continuous clean cycle, 
where excess charge on the array is continuously removed until the external sync pulse is 
received. Once the external sync pulse is received, cleaning of the array stops as soon as the 
current row is shifted, and frame collection begins. 
The camera WinX software (Princeton Instruments, USA) is used to initialize the camera 
settings and collect the CCD images in external triggering mode. The number of exposures, 
exposure time, gain settings, and other camera settings are also configured via the WinView 
software. 
3.2.6.2 Switch 
The switch is capable of being controlled by either a serial RS232 interface or a parallel TTL 
interface with a chip selection signal (strobe). Both methods are implemented in the control 
board, but the parallel interface is used for simplicity and reliability. A combination of three data 
pins controls the switch behavior according to the values in Table 3-2. The strobe pin controls 
when the switch activates the current channel depicted by the data pins independent of when the 
data pins are changed. The strobe pin must remain constant for at least 45µs before and after 
changing from high to low to activate the new channel. Switching occurs after 3ms. Since we are 
only using one galvanometer only need to switch onto one fiber, we utilize Channels 0, 1, and 3. 
Table 3-2. Switch Control Configurations 
 Channel Data Pin 2 Data Pin 1 Data Pin 0 
Off 0 0 0 0 
In 1 – Out 1 1 0 0 1 
In 1 – Out 2 2 0 1 0 
In 2 – Out 1 3 0 1 1 







The 2D galvanometer scanner accepts two differential analog inputs (-10V to 10V correlating to 
the -12.5º to 12.5º scanning angle for the x and y directions). The galvanometer positions are 
determined using two integers from 0 to 999 to discretize the 20V for each direction of the 
galvanometer position). These integers are configured in the Matlab graphical user interface 
shown in Figure 3-7.  
3.2.6.4 Matlab Graphical User Interface 
A Matlab graphical user interface (GUI) on a desktop computer provides an interface to control 
the imaging procedure. The GUI is depicted in Figure 3-7. First, the user selects the source 
positions for an imaging acquisition. The source illumination points must be selected for each 
acquisition since the geometry of each foot is different and the source points should align with 
the fixed position filters. The list of source positions and length of the acquisition indicated in the 
GUI is sent to a control board via serial communication. A list of commands sent to the control 
board is summarized in Table 3-3. 
Table 3-3. Matlab-control board command interface 
Command Header Payload Example 
Set Switch 
Position 
‘M[%03d,#Char]!’ [%03d, Ch#]! ‘M004!003!’ 
Set Galvo 
Position 









‘Y000!’ -- ‘Y000!’ 
Stop Imaging 
Sequence 








‘R000!’ -- ‘R000!’ 
 
 
Figure 3-7. Matlab graphical user interface 
 
Connect to Control Board
Manually Control Optical Switch






Configure the Number of Frames and Exposures to Collect
Save Settings to File and Send to Control Board






3.2.6.5 Control Board 
The control board is built around a microprocessor (PIC32MX695F512H), which is programmed 
to provide the control commands and synchronization of the camera, switch, and galvanometer. 
The control board receives commands and information through serial communication 
(MAX3222). The control board is able to control two 2D galvanometers via a 4-channel DAC 
(AD5664). The 3V outputs of the DAC are amplified and converted to the differential -10V to 
10V input (AD8622). The control board is powered via 5V USB. A voltage reference (ADR423) 
is used to provide 3V TTL signals. To obtain the voltage to control the galvanometer, a charge 
pump (ST662A) and 12V voltage converter (LTC1044A) are used. An image of the control 
board is depicted in Figure 3-8. 
 
 







Figure 3-9. Timing Diagram for Data Acquisition 
 
The timing diagram for an image acquisition is shown in Figure 3-9. When the camera is ready, 
the control board signals the switch to change wavelength, sets the source position via the 
galvanometer, and then triggers the camera to collect an exposure. The control board waits for 
the camera to finish exposure and readout, and then repeats the process until the indicated 
number of frames is captured. 
3.2.7 Integrated Geometry Extraction 
This design to allows for an integrated structured light surface scanner (SLS-2, David Vision 
Systems), comprised of a white light projector and two cameras, to capture the dorsal geometry 
of the foot without obstructing the EMCCD’s view of the foot. The galvanometer is fixed to a 
rail so that it can be slid out of the field of view of the projector and the two cameras of the 
surface scanner. The structured light surface scanner projects sinusoidal light patterns onto the 
foot while the cameras capture the reflection of the disrupted patterns. These disruptions are used 
to create 3D point clouds and a surface mesh. The two cameras capture two different views of 











scan the foot and generate surface meshes. The scanning process takes less than one minute (26 
seconds per scan using 58 patterns and texture). The two scans are fused in the David software 
with a flat bottom to create a closed surface mesh. The surface mesh is post-processed using 
MeshLab and Gmsh to create a volume mesh. The local coordinates of the mesh are translated 
into the global coordinates of the system based on the coordinates of the corners of the slit, 
which are also captured during the surface scan. This allows the surface geometry to be obtained 
within the system before or after data acquisition and enables better co-registration for the source 
point calculation described above.  
 The object geometry is necessary to accurately compute the forward prediction of light 
propagation during the image reconstruction process.  
 






3.2.8 System Enclosure 
The system is constructed on a solid aluminum optical breadboard base (36in x 36in, Thorlabs, 
USA) to hold a light tight enclosure for foot imaging and shelves to hold the system components, 
such as the host computer, lasers, and power supplies. The base sits on four caster wheels so the 
system to be easily moved between locations in the clinic. 
The light tight enclosure is 12in x 12in x 36in and houses the imaging unit, the detection 
unit, the galvanometer scanner from the input unit, and the surface scanning unit. The enclosure 
is built upon several black aluminum rails and optically absorbing black out material to minimize 
ambient light leakage and stray light reflections.  
 To reduce light leakage into the system at the patient interface, a black out material fabric 
is used to enclose the patient’s leg. The fabric is attached to the system and is easily wrapped 
around the calf and secured via Velcro or elastic to prevent ambient light leakage around the 
foot.  
3.2.9 Source Position Extraction 
The source illumination point coordinates on the mesh are needed to model and reconstruct the 
optical properties within the object volume. In this system, a 2D galvanometer scanner guides a 
laser beam to the imaged object by rotating two mirrors along the horizontal (X) and vertical (Y) 
directions. The laser beam enters the scanning system and hits the first X-axis mirror. The X-axis 
mirror deflects the laser to the second Y-axis mirror, which deflects the beam to the object. The 
rotations of the mirrors control the horizontal and vertical deflection of the laser beam to any 
position within the two dimensions, sometimes referred to as the “marking field”. This scanning 





the top of the foot. However, the use of a 2-mirror deflection system leads to geometric 
distortions in the marking field [226]. For example, scanning the laser in a square-shaped pattern 
on a planar surface will produce a pin-cushion shape instead. Additional geometric distortions 
are introduced by any mechanical misalignment of the incoming laser beam. The distortions also 
apply to the laser beam shape, known as beam path distortions, and are caused by the path length 
variations for different portions of the beam. 
A number of approaches have been investigated to model and integrate corrections for 
marking field distortions.  For simple distortions on planar objects, polynomial fitting techniques 
have been used [227]. For more complicated distortions on complex objects, vector analysis has 
been used to model systematic errors resulting from the geometric properties of the scanning 
system [228, 229]. A calibration step is completed to fit the parameters of the model using 
measured values of the marking field. Using the model and fitted parameters to describe the 
system, the rotation of the motors can be adjusted so that the desired position of the laser beam 
can be obtained. However, in this application it is not essential to correct for distortions. It is 
enough to know the final source illumination position despite the distortion. Furthermore, since 
the spot size is small in comparison to the element sizes used in the meshes, we do not consider 
beam path distortions in the scope of this work. Thus, we only need to characterize the geometric 
distortions in the marking field of the scanner.  
To characterize the geometric distortions, map the marking field in 3D using calibration 
measurements from the scanner. We acquire images of a 12x12 point-grid pattern of the laser 
beam deflection from the galvanometer scanner onto a planar platform at 8 known vertical 
heights within the system. The point-grid pattern is obtained by applying equally spaced 





are acquired using the EMCCD camera built into the system. However, the marking field of the 
galvanometer scanner covers an area outside the field of view of the detection unit and it is 
possible to utilize a source position in this area. In order to characterize the entire marking field 
of the galvanometer scanner, we couple the EMCCD camera with a fisheye lens (Bower, 8mm, 
f/3.5). The fisheye lens is able to capture the entire marking field, but introduces a considerable 
amount of distortion. We use standard methods for removing this fisheye distortion that have 
been included in Matlab image processing toolboxes [230]. To ensure the fisheye distortion is 
sufficiently removed, a camera calibration grid pattern is printed on the planar platform so that 
undistorted images should show the regular grid pattern.  
The images are scaled and co-registered to a physical dimension coordinate system. A 
scaling factor based on the known dimensions of the camera calibration grid pattern visible in 
each image is used to scale the images. Together with the known vertical positions of the 
platform within the system, the same camera calibration grid pattern is also used to co-register 
the images.  
Once the images are in a 3D coordinate system, extraction of the pixel location of the 
laser beam grid point in each image determines one point in the 3D marking field. A line through 
all of the points obtained for one (X, Y) rotation pair represents the light beam path from the 
galvanometer scanner. A combination of these lines for different rotation pairs forms a 3D 
marking field that characterizes the geometric distortions. This 3D marking field can be co-
registered and transformed to the mesh using the coordinates of the corners of the rectangular 
transmission window. This co-registered 3D marking field is shown in yellow in Figure 3-11(a).  
The source illumination point can be extracted by first interpolating the laser path for 





intersection of the laser path and the mesh is the source illumination point. The resulting source 
points on the mesh are shown as red dots in Figure 3-11(b). The marking field only needs to be 
generated once, assuming the components remain fixed in relation to each other. 
 
 
Figure 3-11. Source Position Extraction. (a) Interpolated laser paths (red) in the co-
registered galvanometer marking field (yellow) and foot mesh. (b) Calculated source 
positions (red) on foot mesh 
 
This method was verified by comparing extracted source positions to known locations on a block 
phantom. Figure 3-12 shows a plot of the top of the block phantom with known source locations 
in black and the extracted source positions in red. The max error between the actual position and 







Figure 3-12. Plot of the block phantom with known source locations (black) and extracted 
source positions (red) demonstrating a source position extraction accuracy of 0.5mm. 
 
3.3 Image Reconstruction 
3.3.1 Measurement Operator 
In the image reconstruction process, a measurement operator converts the measurements 
collected with the imaging system to the equivalent radiance from the object surface. For fiber-
based systems, all the photons emitted from the detection point are captured by the fiber. In this 
case, we can simply integrate the photons at the fiber location in all directions. However, only a 
portion of the photons emitted from the object surface are collected in non-contact 
measurements. The amount depends on the orientation of the sensor, the imaged object, and the 
generalized optical components the light passes through relative to each other.  
Furthermore, the top and bottom surfaces of the object are at different distances from the 
focal plane. In this system design, the lens aperture f/2.8 results in a shallow focal depth. This 
focal depth does not account for the 8in difference between the top and bottom surfaces of the 





intensities for the object surface while taking this into account, we model the light propagation 
from the object’s surface through the imaging unit and to the CCD chip using a previously 
described method [231, 232]. Then, a linear measurement operator can be constructed to map the 
measurements from the sensor plane to the light intensity distribution on the surface of the 
imaging object. For out of focus surfaces, the radiance is a weighted sum of the detected values 
at various CCD pixels. A brief description of the method is described. 
According to the surface radiation theory, the total radiant power  emitted from a 
surface area , from position  in the direction of  that is captured by the aperture of the 
camera is given by: 
  (3-1) 
where  is the radiation light intensity from the surface,  is the unit normal at , and  is 
the solid angle in the direction of ,  is the solid angle subtended by the aperture through 
the system optical components from point . Assuming no loss of energy from the aperture to 
the CCD, the total power received by the CCD sensor is given by: 
  (3-2) 
where  is the energy transferred per unit area at .  is the radiant flux per unit area on 
the CCD.  is the measureable quantity by the CCD and is given by: 
  (3-3) 
 can be expressed as a function of the surface radiation  where the measurement operator 
 provides a mapping of the spatial distribution of emitted light from the tissue surface  to a 
measureable quantity  on each pixel of the CCD sensor.  is the boundary data and is 
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compared to the prediction during the reconstruction process.  is a measurement operator that 
projects the forward solution  onto the measureable quantity  by the imaging system. A 
raw camera image of a foot phantom is shown in Figure 3-13(b) with the corresponding image of 
mapped pixels in red from the measurement operator. While this shows the binary mapped 
pixels, it is important to note that each detected pixel value is a weighted sum of the surface 
radiation from relevant surface areas on the object. 
 
 



















If the imaging plane is in focus, the sensor plane is the same as the imaging plane. 
However, the sensor plane is offset from the imaging plane in this system, causing a slight 
blurring of both surfaces (see Fig. 6(b)). Knowing the camera parameters (e.g. the object 
distance, image distance, and sensor distance), the ray tracing can account for the mismatch 
between the image plane and the sensor plane. Thus, each pixel of the sensor plane image is a 
weighted sum of the emitted rays from different points on the surface of the foot, effectively 
providing a weighted average.  The measurement operator is the inverse of this mapping such 
that when applied to the detection values at each pixel, we solve for the radiance at each point on 
the surface. Then, these radiance values are used to reconstruct the hemoglobin concentrations 
within the foot. More details on the procedure for constructing the measurement operator ¶ can 
be found elsewhere. 
3.3.2 Reconstruction 
The surface radiance calculated from the measurement operator is directly reconstructed to 3D 
maps of chromophore concentrations or absorption coefficients using a diffusion approximation 
based multispectral reconstruction algorithm [233, 234]. The algorithm reconstructs the relative 
changes from difference data between the target and reference. In vascular imaging, we are 
mainly interested in recovering image contrast based on absorption. Thus, the scattering is 
assumed to be homogenous for throughout the imaged object in these cases. We also assume 
homogenous concentrations of oxyhemoglobin and deoxyhemoglobin for the baseline reference 
state to generate the forward prediction. The ratio of the target data to the reference data scales 





the reconstruction code. The reconstructed values represent the difference in percent change 
relative to the reference state. 
The reconstruction algorithm employs a reduced spaced reconstruction method that 
makes use of a basis function neural network (BFNN) described previously [235]. In brief, a 
basis functions are used to reduce the number of unknowns and to reduce the ill-posed nature of 
the inverse problem. This method is more robust than traditional element-based reconstruction 
methods which are much more sensitive the initial guess, regularization parameter, and 
measurement noise.  
The spatial distribution of chromophore concentrations ù(1, ß, ä) is transformed into a 
linear combination of basis functions and their coefficients ®ê(1, ß, ä)©, where © is a spatially 
invariant vector of weights. We utilize the discrete cosine transform (DCT) function for the basis 
functions and further decompose them into a product of three independent orthogonal basis 
™®8®´®¨≠
ê
© . Using an unstructured node-centered finite-volume approach, a system of 
discretized equations for the diffusion approximation for each wavelength is defined and solved 
iteratively using a restarted GMRES linear solver to obtain a spatial distribution of fluence at 
throughout the medium and at the boundary. Using the DCT basis functions, the multispectral 
inverse problem reduces to solving for a reduced set of weights instead of element-based 
chromophore concentrations: 
 
  (3-4) φ Ci (x, y, z)( ) =
1
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It is important to note that using a multispectral method, we minimize the sum of the objective 








4 Contact-Free DOT System Characterization and Performance 
4.1 Dark Noise and Dynamic Range 
Dark noise is caused by the thermally induced buildup of charge in the CCD over time and is 
dependent on temperature and exposure time. The warmer the camera and the longer the 
integration time, the less uniform the background will appear. The EMCCD is air cooled to 
maintain a temperature of -70º to reduce dark noise. The dark noise level counts for a range of 
integration times between 10ms and 500ms and EM gain factors between 50 and 500 are shown 
in Figure 4-1 in blue, and the background noise level counts for the same parameters are shown 
in orange. The background noise is attributed to the dark noise and any ambient light leakage. 
 
 





The 16-bit CCD has a maximum count level of 65,536. The dark noise count is approximately 
654rms for 75ms integration times across EM gains factors up to 1000 for an effective dynamic 
range of (40dB). This increases to 791 for 300ms integration times (38dB). The background 
count, which includes the dark noise and ambient light leakage into the system, is 656rms and 
792rms for 75ms and 300ms integration times respectively; indicating that the ambient light 
leakage into the system is minimal. 
4.2 Linearity 
The EMCCD camera EM gain calibration values 1-1000 are mapped linearly to the internal 
serial clock voltages that vary the multiplication gain for a one-to-one relationship between 
entered gain value and actual gain. To determine the system detection linearity, the EMCCD 
signal was measured as a function of the laser intensity (within the range between dark noise and 
saturation) through a solid phantom. This was completed for both wavelengths at an EM gain 
factor of 50. The system showed good linearity with a R2 value of 0.999 for both 860nm and 
660nm over the dynamic range of the camera (Figure 4-2(b) left and right, respectively). Similar 
results were found for a gain factor of 5. 
4.3 Stability 
Repeated measurements of a solid block phantom with 10 source positions were taken over a 1-
hour time interval. 3-minute recordings were acquired after the EMCCD reached the cooled 
temperature, and again at 5 minutes, 10 minutes, 20 minutes, 40 minutes, and 1 hour after the 
initial recording with the same experimental settings. The coefficient of variation (CV) was 
calculated for various detector pixels over the 1-hour time interval. The mean CV was 0.63% for 







Figure 4-2. Detection linearity of 860nm and 660nm at different gain settings. (a) EM 
gain factor of 2 for 860nm (left) and 660nm (right) (b) EM gain factor of 50 for 860nm 
(left) and 660nm (right). (c) EM gain factor of 3 (left) and 5 (right) for 860nm. 
 
4.4 Frame-rate 
The system was designed for dynamic imaging of the blood perfusion within the foot, thus the 
speed of acquisition is important. Since each source position and wavelength is sequentially 








source positions. The acquisition time for each wavelength at a source position is approximately 
the integration time plus a 60ms readout time. The frame-rate decreases with increasing source 
positions and integration times. For 10 sources, 2 wavelengths, and a 75ms integration time, the 
frame-rate is approximately 0.33Hz. This results in a high enough temporal resolution to obtain 
time-dependent functional measures to characterize perfusion in the foot.  
4.5 Block Phantoms Experiments 
4.5.1 Block Phantom Fabrication 
A solid block phantom, depicted in Figure 4-3, was used to characterize the system’s ability to 
localize absorbers and to recover varying absorption contrasts. The solid rectangular phantom 
(16.5cm x 6.4cm x 4.5cm) was fabricated using Sylgard® 184 PDMS, titanium dioxide, and India 
ink. The block phantom was made to have an absorption coefficient, µa, of 0.15cm-1 and a 
reduced scattering coefficient, µs’, of 10cm-1 at 650nm (according to [236]). The phantom 
contains several 5mm diameter hollow channels (diameter = 5mm, length = 6.35cm) that pass 
through the block at various locations detailed in Figure 4-3. Five channels are positioned at 
various depths in the center of the block, and two channels are positioned off center at the top 
and bottom of the block. Solid cylindrical inclusions of the same material, but with higher 
absorption (µa = 0.75cm-1, µs’ = 10cm-1 at 650nm), were placed in the hollow channels in 
different configurations. The remaining channels were filled with solid rods of the same optical 







Figure 4-3: Solid block phantom 
4.5.2 Accuracy Measures 
To quantify the quality of the reconstructions, we use the correlation factor  and deviation 
factor . The correlation factor indicates the degree of structural similarity between the exact 
and reconstructed images and ranges from -1 to 1. The deviation factor describes the discrepancy 
in the absolute values of exact and estimated quantities. The closer the correlation factor gets to 
1, and the closer the deviation factor get to 0, the better the reconstruction. Where  and  
are the mean and standard deviations of the absorption coefficient observed spatially, the 
correlation and deviation factors are defined as: 
 
 





4.5.3 Localization Accuracy 
The phantom was imaged with and without the 5x higher absorbing inclusions using 18 source 
illumination positions (as depicted in Figure 4-3), a 55ms integration time and a gain setting of 5. 
32,154 pixel detectors were used to reconstruct µa in a 126,048 tetrahedron volume mesh 
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Fig. 10(a) shows the positioning of the high absorbing inclusions in two configurations. Fig. 
10(b) shows the corresponding reconstruction results in a numeric simulation. Fig. 10(c) shows 
the corresponding reconstruction results after 20 iterations from the data gathered from the 
system. The measures of the quality of the reconstruction are shown in Table 2. 
 
Figure 4-4: Block phantom numeric simulations and experimental results for two 
configurations 
 
Table 4-1: Accuracy of block phantom reconstructions 
 Configuration 1 Configuration 2 
     
Numeric 
Simulation 
0.6607 0.6760 0.7637 0.6760 
Experimental 
Result 
0.6725 0.9534 0.7383 0.9279 
 
4.5.4 Quantitation Accuracy 
The sensitivity of the system to resolve different target-to-background absorption contrasts was 














































phantom were fitted with inclusions of the same silicone material as the block with the same 
reduced scattering coefficient. Due to the one-time-use nature of the molds, we were only able to 
fabricate seven inclusions of the same background properties and two inclusions of 5x 
absorption. Thus, in order to investigate the sensitivity of the system to different absorption 
contrasts, the hollow targets in the block phantom were fitted with clear nylon tubing with 1/16in 
thick walls. The tubing was filled with 4 different ink contrasts (2x: µa=0.3cm-1, 3x: µa=0.45cm-
1, 4x: µa=0.6cm-1, and 5x: µa=0.75cm-1). The results are shown in Figure 4-5. The recovered 







Figure 4-5: Block phantom results with inclusions at 2x-5x contrast in (a) Configuration 
1, and (b) Configuration 2 with the max recovered contrast plotted against the actual 
target contrast 
 
The system was able to localize targets in a simple configuration with the top inclusion offset 
from the bottom inclusion. The localization was also very good for a more complex 
configuration with the top and bottom inclusions inline. Even at 2x contrast, the localization of 
the inclusions was good in both configurations. The localization of the inclusions in the 
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experimental study agreed with the simulation study. However, the reconstructed values of the 
inclusions in the simulation study are higher than that of the experimental results. Overall, the 
quantitative recovery of the absorption coefficient was underestimated. This is a well-known 
phenomenon in DOT. Furthermore, the inclusions at the top of the phantom were consistently 
reconstructed with higher values than the inclusions at the bottom of the phantom. This is 
expected since the sensitivity at the top surface is higher. This is due to the source positions only 
being applied to the top surface, while detectors are utilized both from the top and bottom 
surfaces. This was confirmed in the numeric simulations. Despite the underestimation of the 
absorption coefficient, the recovered contrast increases with increasing target contrast. This 
demonstrates the system’s ability to detect relative changes in absorption. 
4.6 Foot Phantom Experiments 
4.6.1 Foot Phantom Fabrication 
A silicone-based foot phantom, shown in Figure 4-6(a), was fabricated in a similar method as the 
block phantom above. This foot phantom was used to test the system’s ability to resolve more 
complex and realistic vascular systems such as those found at the mid-metatarsal level of the 
foot. Three different water-soluble vessel channel systems were 3D printed and inserted into a 
foot mold (Figure 4-6(b)). These channel systems mimic the three angiosomes found in the distal 
portion of the foot: the dorsalis pedis artery (DPA), medial plantar artery (MPA), and the lateral 
plantar artery (LPA) angiosomes. They start as three main arteries by the heel of the foot 
phantom, and then branch into 8 vessel regions at the mid-metatarsal level, as detailed in Figure 





leaving open channels. Occluded angiosomes are simulated by filling the channels with lower 
absorbing solutions, which represent a decrease in blood pooling. 
 
Figure 4-6: Foot phantom setup. (a) Image of the foot phantom. (b) Model of the three 
vessel structures in the foot phantom. (c) Detailed depictions of each vessel structure 
representing three angiosomes. 
 
4.6.2 Angiosome and Localization Studies 
Seven combinations of the angiosomes were filled with dilutions of India Ink while the 
remaining angiosomes were filled with water. These cases were imaged with 20 source positions 
(as shown in Figure 4-7(h)), a 50ms integration time, and a gain setting of 5. 19,633 pixel 
detectors were used to reconstruct µa in a 39,167-tetrahedron volume mesh (approximately 
18.3mm3/element, 2.635 mm/side). A premade mesh for the foot phantom was co-registered 
from the surface mesh obtained from the surface scanner. The results of the reconstructions after 










Figure 4-7: Foot phantom results for seven inclusion combinations, where black dotted 
circles represent the expected area of the inclusion. Thinner dotted circles in (c), (d), (e), 
and (g) represent uncertain areas due to vessel positioning. The source positions used and 
approximate cross –section depicted is shown in (h). 
 
The black dashed circles represent the actual location of the vessels within the foot phantom, 
which show a reasonable agreement with the reconstruction result in most cases. For example, in 
cases where the LPA angiosome contain the inclusions with diluted ink (Figure 4-7 (a), (d), (f), 
and (g)), the reconstructions show good agreement with the expected locations at the bottom of 
the foot. However, in cases where the MPA angiosome contain the inclusions (Figure 4-7 (b), 
(e), (f), and (g)), the reconstructions show inclusions in the LPA and portions of the DPA 
angiosome where they are not expected. However, we believe that there may have been some 
leakage between inclusion vessel channels. While trying to complete this experiment again, we 
did see a large leakage on the LPA side of the foot while filling the MPA vessels, indicating that 
there was some crossover from the MPA vessels to the LPA vessels. Finally, in the cases where 
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the DPA angiosome contain inclusions (Figure 4-7 (c), (d), (e), and (g)), the results do not 
exactly match the expectations. The results of the DPA reconstructions may be explained by the 
uncertainty in the relative positioning of the vessel structure within the phantom. The uncertainty 
in the vessel positioning comes from the limitations in the precision in fabricating the foot 
phantom. The inflow and outflow vessels of the DPA angiosome (represented by the upper left 
and upper right circles, respectively) have larger diameters than the 4 vessels branched off from 
the arch. The inflow inclusion shows good distinction in the reconstruction in all DPA inclusion 
cases. The outflow inclusion also has a larger diameter, but the reconstruction merges this 
inclusion with the bottom LPA inclusion into the middle depth of the foot. This reveals a 
limitation of the system in resolving depth in this thinner area of the foot. For the two expected 
inclusion areas in the middle of the foot in the DPA angiosome (outlined in thinner black 
circles), the reconstructed results indicate some inclusion, but not to the same contrast as the 
other areas. This may be explained by the smaller vessel diameter and the uncertainty the vessel 
structure positioning. A single line of source positions was used in this experiment, which may 
have been positioned right above or behind the major vessel arch of the DPA angiosome. The 
single line of sources decreased the resolution along the length of the foot. Depending on this 
line of sources exact position relative to the vessel structure, the detection sensitivity to the DPA 
vessel structure changes. We suspect that in this specific setup we had the highest sensitivity just 
behind the arch. At this cross section, the larger inflow and outflow vessels are detected with a 






4.7 In Vivo Imaging Studies in Healthy Feet 
4.7.1 Healthy Foot Case 
We have previously shown that DDOT measurement of the hemodynamics during a venous 
occlusion can distinguish between healthy and affected vasculature [163, 164]. As an initial test 
and proof-of-concept of this system, we imaged a healthy foot during a venous occlusion and 
qualitatively evaluate the results. The venous occlusion is achieved by inflating a pressure cuff at 
the thigh to 80mmHg During the occlusion, venous outflow from the extremity is blocked while 
arterial inflow is left intact such that there is an accumulation of blood in the foot during the 
occlusion. Time-dependent features of this accumulation reveal information regarding the 
vasculature in the lower extremity and the perfusion of blood in the foot.  
The left foot of a healthy volunteer was imaged for approximately 40 seconds of baseline, 
90 seconds of occlusion at 80mmHg, and 50 seconds of recovery. The images were acquired at 
approximately 0.33Hz using 10 source illumination positions in a single line across the foot, a 
75ms integration time, and a gain factor of 50. 22,554 pixel detectors were used to reconstruct 
the relative change in [Hb] and [HbO2] in a foot volume mesh with 59,883 tetrahedron elements 
(approximately 7.5 mm3/element). The reference concentrations of [Hb] and [HbO2] were 
assumed to be 14.69µM and 23.43µM, respectively. The reconstructions were stopped after 10 
iterations, and the final reconstruction of the previous frame was used as the initial guess for the 
next frame. Figure 4-8(a) shows 2D cross sectional maps of the time dependent change in total 







Figure 4-8: Reconstruction results of an in vivo healthy foot during a venous occlusion 
protocol. (a) 2D spatial maps of total hemoglobin concentration [HbT]. (b) Time traces of 
the average [HbT] change in regions of interest within the three angiosomes. 
 
The spatial maps show areas of high [HbT] change at the top and bottom of the foot during the 
venous occlusion. These regions can be attributed to areas in the foot with vasculature and 
correlate with expected areas of vasculature. Extracting these areas using a correlation 
coefficient method used previously [163], we can track the time course of the total hemoglobin 
levels. Specifically, the mean [HbT] value in the volume of the foot being imaged is calculated 
for each time point to produce a time trace of the average [HbT] within the foot. Similar time 
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for each control volume is calculated. We used a threshold of >0.65 to define regions of interest 
(ROI) that represent the vascular areas of the foot. We further segment the ROIs into three 
angiosome regions and plot the mean [HbT] values over time in each of the angiosome ROIs in 
Figure 4-8(b), with the DPA shown in blue, MPA shown in orange, and the LPA shown in green.  
4.7.2 Repeatability 
This experiment was repeated on the same foot on a second day and compared to the initial 
experiment to test the in vivo repeatability of the system. The resulting spatial maps and time 
traces matched the initial experiment. The spatial distribution of [HbT] at the peak of the 
occlusion had a high correlation factor   of 0.9967, and a low deviation factor   of 0.1117. The 
2D spatial maps of [HbT] at the peak of the occlusion on both days are shown in Figure 4-9.  The 
time-traces also had a high correlation factor of >0.997 for each angiosome. 
 
Figure 4-9: 2D spatial maps of [HbT] change at the peak of the vneous occlusion on (a) 
Day 1, and (b) Day 2, showing very similar areas of blood perfusion. 
 
The initial in vivo study on a healthy foot shows the system’s ability to capture hemodynamics 
within the foot during a venous occlusion. The 2D maps of the total hemoglobin change reveal 
regions of interest at the top and bottom of the foot that match the vascular areas of the mid-















occlusion from those regions of interest also match the expected trends from previous work. The 
dynamic change of hemoglobin reveals important information in evaluating arterial status. 
Furthermore, the same foot was imaged on a different day and the resulting 2D maps and time-
traces had high correlations with the first day. This is an initial demonstration of the system’s 
ability to reliably measure the hemodynamic changes. However, slight differences between days 
could be attributed to physiological differences arising from natural day-to-day differences. This 





4.8 Comparison to Fiber-Based DDOT Systems 
A comparison of the system characteristics for the non-contact system and the fiber-based DOT 
system used previously for PAD [213] is presented in Table 4-2.  
Table 4-2: Comparison of system characteristics for this contact-free DDOT system and 
the fiber-based DDOT system used previously for vascular optical tomography 
System Characteristic Contact-Free DDOT Fiber-Based DDOT [213] 
Mode of Operation CW CW 
Number of Sources 10 (typical)* 16 
Number of Detectors 22,500 (typical)** 32 
Wavelengths 2 2 
Total Data Points 450,000*** 1024 
Frame Rate ~0.33Hz**** ~6Hz 
Dynamic Range ~40dB ~190dB 
Dark Noise 650counts 20-400µV 
CV (%) < 0.9% 0.05-0.5% 
SNR 29dB 48dB 
System Size (including cart) 2ft x 2ft x 3ft 2ft x 2ft x 3ft 
* The number of sources used is programmable and can vary. 
** The number of detectors varies based on the size of the foot. 
*** The total number of data points varies with the number of detectors.  
       It is calculated for the typical number of sources and detectors shown in the table. 
**** The frame rate varies based on the number of sources and integration time.  
         It is reported here for 10 sources and a 75ms integration time. 
 
In addition to the contact-free interface, this new system increases the number of data points 
collected by improving the detection resolution. However, this comes at the cost of frame rate, 
dynamic range, and signal-to-noise ratio (SNR). The fiber-based DDOT system uses source 





simultaneously. Since the contact-free system requires sequential illumination of each 
wavelength and longer integration times, the system has a much lower frame rate of 
approximately 0.33Hz compared to 6Hz for the fiber-based system. The SNR is calculated as: 
N!` = 20 log-2
á
±  
where ± is the standard deviation around the average measurement á (an 11x11pixel region in 
the case of the contact-free system). The SNR of the fiber-based system (48dB) is higher 
compared to the contact-free system (29dB). The dynamic range of the photodetectors in the 
fiber-based system is much higher than the 16-bit CCD. However, with the improvement in CCD 
and CMOS technologies, the dynamic range and sensitivity of the system may be increased by 






In this work, we developed a multi-view contact-free DDOT system to measure the 
hemodynamics in the foot. The measurement operator allows reconstruction of data from 
multiple imaging planes outside of the short focal depth of the f/2.8 lens. This enables the upright 
design of the system, which is small enough to be easily moved and stored in the clinical setting. 
In addition, the fiber-less tissue interface reduces the setup time and avoids issues common with 
fiber-based systems. The advantages of the non-contact scheme make it suitable for the clinical 
setting and for patients with open wounds and ulcers. The system was experimentally validated 
with tissue-mimicking phantoms. Its ability to localize and quantify changes in absorption was 
demonstrated. Repeated in vivo tests demonstrated the successful non-contact imaging of total 
hemoglobin changes during a venous occlusion.  
The system is capable of imaging at 0.33Hz with 10 source positions and an integration 
time of 75ms. This is sufficient to capture hemodynamics during a one-minute long venous 
occlusion. The frame-rate can be increased if necessary by utilizing less sources or shorter 
integration times and offsetting the decreased signal with EM gain. The frame rate could also 
further be improved by using structured illumination patterns instead of single point sources. 
This will be investigated further in future studies with more feet and testing in PAD patients. 
Imaging deeper tissues with CW DOT comes with many challenges, further aggravated 
when using non-contact approaches. The scattering nature of photons in tissue decreases the 
sensitivity of DOT exponentially with increasing depth. The perfusion within the foot is 
generally close to the tissue surfaces and DOT’s poor depth localization does not have a large 





traveling through deep tissues. The penetration depth of light depends on the wavelength, 
intensity, (s-d separation), and the optical properties (i.e. the absorption and scattering) of the 
medium. With non-contact imaging with wide field detectors, overall light collection efficiency 
further limited by the area and acceptance angle from which the light emitted from the tissue can 
be transferred to the CCD detector.  
We demonstrated the system’s ability to resolve inhomogeneity within tissue-mimicking 
block and foot phantoms. The spatial structure of the reconstruction was good, but the actual 
values were underestimated. This underestimation is in part due to inherent systemic offsets in 
the instrument and reconstruction method. However, the main focus in vascular imaging in the 
foot is on relative change. The image contrast was preserved in the block phantom studies, where 
varying levels of contrasting inclusions show a relative increase in the reconstructed contrast 
with increasing target contrast for both the top and bottom inclusions. Although the reconstructed 
contrast is less than expected based on peak contrast, this effect has been observed previously 
and has been attributed to the spreading of contrast, or the broadening of the spatial target in the 
reconstruction compared to the true target dimensions. This contrast is important in dynamic 
studies where time-dependent changes are used instead of absolute concentrations. The block 
phantom studies demonstrate the system’s ability to reconstruct relative changes in absorption 
and to accurately localize those changes. The system is more sensitive to changes at the top of 
the foot. This can potentially be adjusted for with a depth dependent correction factor. Finally, in 
vivo studies in a healthy foot demonstrate the potential of the system to evaluate the vasculature 
in the lower extremities by measuring the perfusion in the foot during a venous occlusion. 
Although its utility was demonstrated, the current instrumentation setup is not fully 





density of reflection filtering may be better optimized. Another feature of the system that could 
be improved is the specular reflection rejection. The reflection and scattering at the surface of the 
object poses a significant challenge in reflectance geometry non-contact imaging. Specular 
reflections and weakly scattered light can be minimized by using crossed linear polarization or 
polarization-selective detection. Diffusely scattered light from tissue is randomly polarized while 
directly reflected light or weakly scattered light maintains the polarization of the source. 
Furthermore, different wavelengths maybe be a better compromise between achieving higher 
transmission efficiency and ability to reconstruct hemoglobin concentrations. For example, a 
780nm wavelength would improve light detection efficiency over 660nm. To overcome 
sensitivity heterogeneity, the system could be modified to add the ability to project source 
positions on the bottom of the foot as well as the top. For this setup, the advances in CMOS 
technology may make it feasible to utilize two cameras in order to optimize dynamic range.  
Even without these improvements, we demonstrated that the current system is sufficient 
for measuring blood flow in the foot. The main advantages of this system are its non-contact and 
multi-view capabilities. By implementing this system, we have facilitated further investigation of 
PAD. This system provides a functional measure of the perfusion in the foot, which fills a gap in 
the current clinical evaluation tools for PAD. This system may play a role in diagnosing, 
evaluating, and treating PAD. For example, this system may prove useful in revealing under-
perfused angiosomes within the foot and informing revascularization procedures. In addition, we 
may gain a better understanding of the link between blood perfusion and wound healing with 
future studies. This system can also be generalized to imaging other tissues such as the hand and 





Summary and Future Work 
4.10 Summary 
In an ongoing study to monitor revascularization procedures, an interim analysis of 51 patients 
revealed interesting trends and demonstrated the potential utility of DOS measurements. The 
DOS measurements of the hemodynamics during a venous occlusion are sensitive to the 
perfusion in the foot. Better perfusion is associated with a faster accumulation of total 
hemoglobin during the venous occlusion. Hampered perfusion due to arterial stenosis is marked 
by a slower accumulation of total hemoglobin. This accumulation was quantified by calculating 
the normalized pooling rate (NPR). We found that there was no significant difference in NPR for 
patients not receiving and intervention (p=0.25), but did find a significant difference for patients 
undergoing revascularization (p<0.0001).  
  Angiosome-directed revascularization hold promise for increasing effectiveness of 
cancer treatment, but evaluating its use optimizing their use may require the development of new 
assessment strategies. We found that it may be possible to identify patients who maintain a 6-
month overall improvement within a month after revascularization. The normalized follow-up 
perfusion of directly revascularized angiosomes was significantly different between patients that 
maintained improvement and patients who did not (p=0.05), but there was no significant 
difference between groups when considering all angiosomes (p=0.65). We believe this is related 
to the arteriogenic related vascular remodeling response to revascularization, though further 
investigation is needed to fully understand on confirm revascularization induced vascular 





hemodynamically significant changes due to revascularization. The DOS measurements can 
provide valuable information on the temporal dynamics of vascular response to 
revascularization. Positive remodeling to maintain an increased perfusion from the intervention 
can be indicative of revascularization success. Early identification of failed revascularization 
may improve patient outcomes by providing guidance on which patients might benefit from 
other additional therapies before overt failure occurs. While these results show some promise, 
the study is ongoing further analysis with more patients is needed to confirm these trends. 
Overall, this interim analysis underscores the potential value in evaluating local angiosome 
perfusion within the first few weeks of revascularization. 
 The DOS system used in this study provides valuable information in a portable form 
factor, but it has limitations. The system employs contact-based patches to measure localized 
perfusion. Localized contact-based measurements are highly dependent on the location of the 
probe and the quality of contact. To address these issues, we designed and developed a novel 
multi-view non-contact CW DOT system capable of imaging hemodynamics in the foot. This 
system provides 3D images of perfusion through the foot with a non-contact interface. The 
system was characterized and validated, demonstrating the successful non-contact imaging of 
total hemoglobin changes during a venous occlusion.  
The main advantages of this system are its non-contact and multi-view capabilities. The 
non-contact interface is most suitable for the clinical setting and for patients with open wounds 
and ulcers. The multi-view design of the system enhances the tomographic capabilities of the 
system, which provides several advantages over spectroscopic measurements. For example, the 





of blood flow. Perfusion measurements that are more representative of the blood flow through 
the whole angiosome can be extracted.  
By designing and implementing this system, we have facilitated further investigation of 
PAD using DOT techniques. This system may play a role in diagnosing, evaluating, and treating 
PAD. For example, this system may prove useful in revealing under-perfused angiosomes within 
the foot and informing revascularization procedures. In addition, we may gain a better 
understanding of the link between blood perfusion and wound healing with future studies. This 
system can also be generalized to imaging other tissues, the hand and fingers in rheumatoid 
arthritis, for example.  
The advantages of diffuse optical imaging techniques are its low cost and its non-
invasive, non-ionizing, and contrast-free sensitivity to functional parameters of tissue. These 
techniques are particularly useful for PAD patients where perfusion is a critical biomarker, 
exogenous contrast is often contraindicated, and routine and repeated monitoring is necessary. 
This work reveals the potential of optical imaging for monitoring and evaluating 
revascularization success. DOI can enable earlier and more effective clinical decision making to 
improve patient care and outcomes. In this work, I also develop novel DOT instrumentation to 






4.11 Future Work and Outlook 
4.11.1 Measurement Methods and Instrumentation 
4.11.1.1 Imaging Protocol  
While the imaging protocol applied in this study was able to produce valuable perfusion 
measurements, the sensitivity of the measurements can be improved by optimizing the 5-phase 
imaging protocol. Specifically, future imaging protocol studies should aim to understand the 
effect of the length of venous occlusion, length of venous occlusion recovery, and repeated 
venous occlusions in both healthy and affected individuals.  
4.11.1.2 Feature Selection 
This work focused on a single robust feature to capture the hemodynamics during the venous 
occlusion (i.e. the normalized pooling rate). More sophisticated classification algorithms could 
also provide alternative ways of quantifying perfusion and could extend this work to use multiple 
image parameters to increase sensitivity and discriminate revascularization success and failure.  
4.11.1.3 DOS Patch Interface 
The patches and toe clip in the current DOS system are capable of obtaining the necessary 
measurements for this pilot study, however design and interface can be improved for future 
clinical use. The patches and cabling are rigid and heavy such that obtaining good contact on the 
foot difficult. An alternative to using Velcro to attach the probes could also aid in improving 
probe contact with the tissue. Additionally, due to the large anatomic differences of the forefoot 
and toe, there it is often not possible to obtain contact using the toe clip. The measurements 





4.11.2 Clinical Impact Outlook 
The study outlined in this thesis focuses on determining whether DOS is useful in evaluating 
whether an initial intervention was successful. However, there are other important areas of PAD 
management where DOI may be beneficial. In addition to the importance of revascularization 
monitoring, hemodynamic assessment for diagnosis and treatment direction are equally relevant.  
4.11.2.1 Screening for PAD 
Up to 50% of PAD patients are asymptomatic and the disease progresses similarly to 
symptomatic patients [25]. An effective method of screening is imperative to reduce the number 
of patients presenting with advanced stages of PAD, where tissue and limb loss are prevalent. 
Patients with asymptomatic PAD have an increased risk of adverse cardiovascular events and 
benefit from identification to provide risk factor modification and medical therapies to 
effectively manage the disease [2, 6, 64, 237]. DOT measurements of perfusion in the foot may 
be the most effective method of screening. We have previously demonstrated promising results 
for PAD detection [163, 164] and the development of an easy-to-use DOT system in this work 
moves this technology closer to clinical use.  
4.11.2.2 Ischemic Wound Healing and Macro- and Microcirculation Assessment 
Since failed healing of wounds is a significant factor leading to amputation, wound healing has 
garnered increased attention in the management of PAD including a new wound classification 
scheme for limb threat [8]. Multiple factors are involved in wound healing ability and it is 
considered a multidisciplinary effort to treat the wound itself and to increase wound perfusion. In 
addition to infection, there is a consensus on the importance of adequate macro and 





peripheral neuropathy where the level of microcirculatory impairment is increased [176]. Since 
microcirculatory impairments can lead to choke vessel and collateral network dysfunction, 
evaluation of both macro- and microcirculation is important. 
There is still a debate on what tools are useful in examining the macro- and 
microcirculation. Transcutaneous oxygen measurements (TcPO2), skin perfusion pressure [100, 
238, 239], indocyanine green fluorescence angiography [210, 240, 241], laser Doppler [242], 
angiographic wound blush [243] [244] [239], and skin temperature have been used as indicators 
of the healing potential of a wound. DOI methods may complement other microperfusion 
measurements to give a complete picture of the relevant perfusion after revascularization for 
wound healing. These methods may be beneficial in describing the wound perfusion 
environment in future studies specifically targeting wound healing. 
4.11.2.3 Revascularization Planning, Execution, and Monitoring 
Interest in angiosome-directed revascularization has grown over the last few years, but current 
research has been limited to wound healing. This is no doubt due to the adverse implications of 
non-healing wounds on limb loss and survival. Current research further motivated by the 
importance in understanding the added complexity for tissue regeneration in CLI patients. 
However, there is also an opportunity to improve patient outcomes with the increased use of 
endovascular revascularizations in IC patients to prevent progression to CLI.  
 The target angiosome for wound-directed revascularization is obvious, but it is less 
obvious in IC patients. In this case, DOI can serve indicate which angiosomes are underperfused 
and in need of revascularization. DOI perfusion measurements may also help guide the extent of 





of the perfusion in the foot may inform the interventionist on whether additional arteries need to 
be revascularized. This has the potential of reducing the detrimental progression of the disease 
and mitigate the need for secondary procedures [170]. DOI is a promising tool to prospectively 
evaluate the angiosome concept in future studies. 
4.11.2.4 Therapeutic Revascularization 
There is significant interest in developing therapeutic revascularization strategies for patients that 
are not candidates for endovascular or surgical revascularization. These strategies aim to 
promote angiogenesis and arteriogeneisis through gene therapy, cell therapy, or protein-based 
therapy in patients with PAD [245, 246]. Despite promising initial results in animal models, 
these therapies have not yet been proven effective in the clinic [247]. In these studies, there is a 
lack of an effective method of evaluate the effect of the treatment on distal perfusion [189]. DOI 
may provide a simple yet effective method of evaluating the effect of therapeutic approaches in 
the clinical investigation of these therapies.  
4.12 Conclusions 
Diffuse optical imaging techniques are well suited for performing perfusion measurements in 
PAD patients. Its value lies in its non-invasive and cost-effective ability to measure 
hemodynamic parameters affected by the disease. In this thesis, the development of DOT 
instrumentation for PAD and the utility of DOS in monitoring PAD revascularization is 
demonstrated. However, the role of diffuse optical imaging in PAD patient care is not limited to 
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